<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:dcterms="http://purl.org/dc/terms/"
   xmlns:ns4="http://bio2rdf.org/drugbank_vocabulary:"
   xmlns:owl="http://www.w3.org/2002/07/owl#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:void="http://rdfs.org/ns/void#"
>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00072">
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00322"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01005"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3814"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00072"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00531"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00928"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00026_DB00072"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00262"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01181"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00023_DB00072"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00087"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00111"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01042"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01380"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00398"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00993"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00544"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2782"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00620"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00631"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3821"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01177"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00081"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00755"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB04572"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB05401"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00108"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00619"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00488"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00959"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00541"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00443"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01030"/>
    <ns4:toxicity>Administration of trastuzumab can result in ventricular dysfunction and congestive heart failure. Risk of cardiotocity is especially elevated in patients recieving concurrent anthracycline or cyclophosphamide therapy.</ns4:toxicity>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00054_DB00072"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3819"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00352"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:3811"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00877"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00515"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f3c8421e0e9dea2efd27bdb8b64f364a"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00552"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00570"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:a885e3085a017e7fb84e228d9e93b7ff"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3815"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01280"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00853"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01024"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00317"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00004_DB00072"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00290"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB04868"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00773"/>
    <rdfs:label xml:lang="en">Trastuzumab [drugbank:DB00072]</rdfs:label>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:567"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB06372"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:5f4df6d410318c0872a704ea3ca60a82"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01008"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01168"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00741"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00970"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:e09e762fa34f3beb62f55d246bcf3691"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3817"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00072_2"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:180288-69-1"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/uniprot:P01857"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00091"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00888"/>
    <ns4:pharmacology>Used in the treatment of HER2-positive breast cancer. HER2 protein overexpression is observed in 25%-30% of primary breast cancers.Trastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumorcells that overexpress HER2. It is a mediator of antibody dependent cellular cytotoxicity, in that the binding of the antibody to HER2 overexpressing cells leads to preferential cell death.</ns4:pharmacology>
    <ns4:category>Approved</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00563"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00095"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00958"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00997"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00072_3"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:16f7cb70c41fa5afd1af07c50b5f4224"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00688"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00526"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2240692"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L01XC03"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3820"/>
    <ns4:synonym>Anti HER2</ns4:synonym>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00051_DB00072"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01101"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2103059"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01229"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00851"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01248"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00361"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00694"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01206"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA451743"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00305"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00078"/>
    <ns4:indication>For treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.</ns4:indication>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Trastuzumab"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:50242-134-68"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00687"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:32c3298d35912d4688d23c5eb64805d1"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:1102"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00074"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00073"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00276"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/trastuzumab.html"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01285"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:784"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/genbank:J00228"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00242"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00635"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00059_DB00072"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00428"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00987"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00075"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00005_DB00072"/>
    <ns4:biotransformation>Most likely removed by opsonization via the reticuloendothelial system.</ns4:biotransformation>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01281"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01196"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00444"/>
    <dcterms:description xml:lang="en">A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*</dcterms:description>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00065_DB00072"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3816"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00480"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00860"/>
    <ns4:category>Biotech</ns4:category>
    <ns4:volume-of-distribution>* 44 mL/kg</ns4:volume-of-distribution>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00291"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01268"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00385"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00445"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01234"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00864"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00530"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3818"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic/trastuz.htm"/>
    <ns4:half-life>average 28.5 days</ns4:half-life>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00072"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01041"/>
    <ns4:mechanism-of-action>Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.</ns4:mechanism-of-action>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01033"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01073"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00441"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01204"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00762"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:844"/>
    <ns4:brand>Herceptin</ns4:brand>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00072_1"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00990">
    <ns4:brand>Aromasin</ns4:brand>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_18"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_3"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:substructure>Isoprenes</ns4:substructure>
    <ns4:mechanism-of-action>Breast cancer cell growth may be estrogen-dependent. Aromatase (exemestane) is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromatase inhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breast cancer. Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation, an effect also known as "suicide inhibition". Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on the adrenal biosynthesis of corticosteroids or aldosterone. This reduction in serum and tumor concentrations of estrogen delays tumor growth and disease progression. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme.</ns4:mechanism-of-action>
    <ns4:indication>For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.</ns4:indication>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8be1de9191eec2dec03cd80888b77ff5"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:4953"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_8"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_12"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L02BG06"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_10"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_5"/>
    <dcterms:description xml:lang="en">Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation.</dcterms:description>
    <ns4:protein-binding>90% (mainly α1-acid glycoprotein and albumin)</ns4:protein-binding>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C08162"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:02f2f00d056c05b20f4f521d91edeeae"/>
    <ns4:substructure>Alkanes and Alkenes</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_17"/>
    <ns4:category>Approved</ns4:category>
    <ns4:half-life>24 hours</ns4:half-life>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:2458e982109b40327f8f0797b4025ae0"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0009-7663-04"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2242705"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:food-interaction>High-fat meals increase plasma exemestane concentrations by approximately 40%.</ns4:food-interaction>
    <ns4:absorption>42%</ns4:absorption>
    <ns4:substructure>Steroids and Steroid Derivatives</ns4:substructure>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:b086be3f9ca0e0ae5dbf28b1b8ba4215"/>
    <ns4:substructure>Carbonyl Compounds</ns4:substructure>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Exemestane"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_11"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/exemestane.html"/>
    <ns4:manufacturer>Pharmacia and upjohn co</ns4:manufacturer>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_7"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:60198"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46508243"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:3811"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2409059"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00990"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00990"/>
    <ns4:toxicity>Convulsions</ns4:toxicity>
    <ns4:biotransformation>Hepatic</ns4:biotransformation>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00990_2"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_14"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_6"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3811"/>
    <ns4:substructure>Ketones</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:54278"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_16"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_19"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D00963"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_13"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_15"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:4808616"/>
    <ns4:synonym>Exemestano [INN-Spanish]</ns4:synonym>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:107868-30-4"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_4"/>
    <rdfs:label xml:lang="en">Exemestane [drugbank:DB00990]</rdfs:label>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <ns4:pharmacology>Aromatase is an enzyme that converts hormones to estrogen in the body's adrenal glands. The aromatase inhibitors (AIs) are drugs that reduce estrogen levels by blocking the action of aromatase in the adrenal glands. The selective AIs (SAIs) selectively reduce levels of estrogen without interfering with levels of other steroid hormones that are produced by the adrenal gland. Drugs in this class include anastrozole (Arimidex &amp;trade;), letrozole (Femara &amp;trade;) and exemestane (Aromasin &amp;trade;).</ns4:pharmacology>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00990_1"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic3/exemest.htm"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00990_9"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00570">
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic3/vinblastine.htm"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_13"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01097"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00220_DB00570"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB00976"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_18"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Vinblastine"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB00619"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6144"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB00705"/>
    <ns4:substructure>Tryptamines and Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00224_DB00570"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00196_DB00570"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_5"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01026"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:865-21-4"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pdb:KAR"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:12773"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB00951"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:03573043c56b8a12acc4dc5433d0a127"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01149"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00570_1"/>
    <ns4:substructure>Carboxylic Acids and Derivatives</ns4:substructure>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2449"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB00622"/>
    <ns4:substructure>Glycerol and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_12"/>
    <ns4:substructure>Imines</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_11"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:pharmacology>Vinblastine is a vinca alkaloid antineoplastic agent. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units: vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (&lt;i&gt;Catharanthus roseus&lt;/i&gt;) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects &lt;i&gt;in vitro&lt;/i&gt;. Vinblastine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.</ns4:pharmacology>
    <ns4:manufacturer>Eli lilly and co</ns4:manufacturer>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00570"/>
    <ns4:category>Antineoplastic Agents, Phytogenic</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_17"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:b9db2fe4cd4014a788856441f9d848b8"/>
    <ns4:mechanism-of-action>The antitumor activity of vinblastine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinblastine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death.</ns4:mechanism-of-action>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01320"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_16"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01167"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB00673"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:9dfa5b979da8b97ce212a15e4fa88687"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_10"/>
    <ns4:substructure>Pyrrolines</ns4:substructure>
    <ns4:biotransformation>Hepatic. Metabolism of vinblastine has been shown to be mediated by hepatic cytochrome P450 3A isoenzymes.</ns4:biotransformation>
    <ns4:substructure>Pyrroles</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_9"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:776"/>
    <ns4:substructure>Indoles and Indole Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01072"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01264"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:464e0508f3faa406e1fc1d033901558c"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:fd74c0323621ae5c390f3166a448d2ee"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01110"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2183056"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/vinblastine.html"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_20"/>
    <ns4:substructure>Short-chain Hydroxy Acids</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB00701"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6137"/>
    <dcterms:description xml:lang="en">Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)</dcterms:description>
    <ns4:substructure>Pyrrolidines</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00503_DB00570"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA451877"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00108_DB00570"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB06695"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB00872"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:862"/>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/bindingdb:50012278"/>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:substructure>Alcohols and Polyols</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01263"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_6"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:241903"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L01CA01"/>
    <ns4:substructure>Phenethylamines</ns4:substructure>
    <ns4:brand>Nincaluicolflastine</ns4:brand>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_15"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB06145"/>
    <ns4:toxicity>Oral, mouse: LD&lt;sub&gt;50&lt;/sub&gt; = 423 mg/kg; Oral, rat: LD&lt;sub&gt;50&lt;/sub&gt; = 305 mg/kg.</ns4:toxicity>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:6211"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:1629"/>
    <ns4:half-life>Triphasic: 35 min, 53 min, and 19 hours</ns4:half-life>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01601"/>
    <ns4:substructure>Acetates</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01369"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1735"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00570"/>
    <ns4:substructure>Anisoles</ns4:substructure>
    <ns4:substructure>Phenyl Esters</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01232"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4119"/>
    <rdfs:label xml:lang="en">Vinblastine [drugbank:DB00570]</rdfs:label>
    <ns4:substructure>Aliphatic and Aryl Amines</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:55390-091-10"/>
    <ns4:route-of-elimination>The major route of excretion may be through the biliary system.</ns4:route-of-elimination>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1588"/>
    <ns4:substructure>Phenylpropylamines</ns4:substructure>
    <ns4:substructure>Amphetamines</ns4:substructure>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:161"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_7"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_4"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:9d5e562a23555c1c206c9bb0a13cd884"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01211"/>
    <ns4:substructure>Piperidines</ns4:substructure>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00570_2"/>
    <ns4:substructure>Carbonyl Compounds</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01319"/>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00570"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00199_DB00570"/>
    <ns4:protein-binding>98-99%</ns4:protein-binding>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00305_DB00570"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:27375"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_8"/>
    <ns4:substructure>Alkanes and Alkenes</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_3"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:4b5c0bb3f1d90576a038a3f972025295"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_14"/>
    <ns4:substructure>Phenols and Derivatives</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46504550"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00252_DB00570"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:6210"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:6212"/>
    <ns4:indication>For treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.</ns4:indication>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB00908"/>
    <ns4:substructure>Anilines</ns4:substructure>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:substructure>Phenylacetates</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C07201"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB00954"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00570_19"/>
    <ns4:category>Approved</ns4:category>
    <ns4:category>Small molecule</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB01036"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00570_DB00582"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00675">
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6013"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:pharmacology>Tamoxifen belongs to a class of drugs called selective estrogen receptor modulators (SERMs), which have both estrogenic and antiestrogenic effects. Tamoxifen has the same nucleus as diethylstilbestrol but possesses an additional side chain (&lt;i&gt;trans&lt;/i&gt; isomer) which accounts for its antiestrogenic activity.</ns4:pharmacology>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_15"/>
    <ns4:substructure>Anisoles</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00619_DB00675"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:de5d3bd460be252fe35f438d64ddadaf"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:00c2f32b55e8cc06274097d4199e4d5a"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8d44276870e140a7b9bd40131dc9a54c"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6104"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00554_DB00675"/>
    <ns4:brand>Citofen</ns4:brand>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00208_DB00675"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/bindingdb:20607"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00872"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01319"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:869"/>
    <ns4:category>Approved</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01104"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00752"/>
    <ns4:substructure>Phenyl Esters</ns4:substructure>
    <dcterms:description xml:lang="en">One of the selective estrogen receptor modulators with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium. [PubChem]</dcterms:description>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01072"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_6"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:cbbd884c8c413b3ad5e05bace2ac150c"/>
    <ns4:substructure>Aliphatic and Aryl Amines</ns4:substructure>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4200"/>
    <ns4:substructure>Alkanes and Alkenes</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:bc1b31f2f07bd704965dbd5da5c48221"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:5ab3a3b5174abd2947f30ff88d5efc3d"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_7"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00976"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:bb6b2f332c9c4f014e10fb092ec58203"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1588"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00712"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:b81519b72ff4a65dd7150dfb62d226f9"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01167"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:2015313"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:f083c84116013f53b6bd6d8390877005"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6024"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0378-0144-91"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB04868"/>
    <ns4:category>Antineoplastic Agents, Hormonal</ns4:category>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01242"/>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4118"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:cd2f623e62449b78f409b20557f728db"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:caa2f904b4b08155f8e4a58d9222f4a4"/>
    <ns4:route-of-elimination>The drug is excreted mainly as polar conjugates, with unchanged drug and unconjugated metabolites accounting for less than 30% of the total fecal radioactivity.</ns4:route-of-elimination>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00458_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01075"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB06228"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00477_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00784"/>
    <ns4:substructure>Isoprenes</ns4:substructure>
    <ns4:biotransformation>Hepatic. Tamoxifen is extensively metabolized after oral administration. N-Desmethyl-tamoxifen is the major metabolite found in plasma. N-Desmethyl-tamoxifen activity is similar to tamoxifen. 4-hydroxy-tamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. 4-Hydroxy-tamoxifen formation is catalyzed mainly by cytochrome P450 (CYP) 2D6, and also by CYP2C9 and 3A4. At high tamoxifen concentrations, CYP2B6 also catalyzes 4-hydroxylation of the parent drug. 4-Hydroxy-tamoxifen possesses 30- to 100-times greater affinity for the estrogen receptor and 30- to 100-times greater potency at inhibiting estrogen-dependent cell proliferation compared to tamoxifen. </ns4:biotransformation>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00615_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00501_DB00675"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c0b36bcdbdbd6a3cba0bde8bf6364b8c"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00679"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8b94de7669b3b2ef38c3f4637a78f8a8"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB06708"/>
    <ns4:toxicity>Signs observed at the highest doses following studies to determine LD&lt;sub&gt;50&lt;/sub&gt; in animals were respiratory difficulties and convulsions.</ns4:toxicity>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:48a11191de26f01206883b656f84660f"/>
    <ns4:synonym>Tamoxifen Citrate</ns4:synonym>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00675_2"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00224_DB00675"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:6127425"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00755"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L02BA01"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_19"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D00966"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00496_DB00675"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6016"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00205_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00907"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:f99848d0f3e57f01a67054e126adc057"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_18"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_17"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6101"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8203e6d19514e57d2398d84da2a8d96f"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01264"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4924"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00359_DB00675"/>
    <ns4:mechanism-of-action>Tamoxifen binds to estrogen receptors (ER), inducing a conformational change in the receptor. This results in a blockage or change in the expression of estrogen dependent genes. The prolonged binding of tamoxifen to the nuclear chromatin of these results in reduced DNA polymerase activity, impaired thymidine utilization, blockade of estradiol uptake, and decreased estrogen response. It is likely that tamoxifen interacts with other coactivators or corepressors in the tissue and binds with different estrogen receptors, ER-alpha or ER-beta, producing both estrogenic and antiestrogenic effects.</ns4:mechanism-of-action>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:2733526"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01232"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00196_DB00675"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00705"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00608_DB00675"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:b5068be13fc7ac7529640981857cc1b1"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f5a2c060dbdf170bf7617e432f4c60d9"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_3"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01186"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00715"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4119"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_14"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:a96969106e65d009febb5975de66e573"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01026"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01601"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01050"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:5718"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00281_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01101"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:91f9748c3ea6261285a6e7a6a2529697"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00243_DB00675"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:22ae8eadff4db6c0d61b66b8ec62d2d2"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic/tamox.htm"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46505515"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00503_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01211"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00357_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00763"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB06268"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA451581"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00328_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00220_DB00675"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4757"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/tamoxifen.html"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6107"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00675_1"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:half-life>Distribution t&lt;sub&gt;1/2&lt;/sub&gt;=7 to 14 hours; Elimination t&lt;sub&gt;1/2&lt;/sub&gt;=5 to 7 days; Elimination t&lt;sub&gt;1/2&lt;/sub&gt; of N-desmethyl-tamoxifen=9-14 days.</ns4:half-life>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01149"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:776"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/iuphar:1016"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00476_DB00675"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/gtp:1016"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4604"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:3811"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:9396"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6030"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:03b7a4cb752e2b225aaf991e3c310eed"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_11"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_10"/>
    <rdfs:label xml:lang="en">Tamoxifen [drugbank:DB00675]</rdfs:label>
    <ns4:manufacturer>Rosemont group ltd</ns4:manufacturer>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Tamoxifen"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pdb:OHT"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00322_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00908"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:3c06450c60a89e25badc81817a30a693"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:3f8f00f26ee8d17fe4cc84a11e5f1c98"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00502_DB00675"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_16"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2237460"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_5"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00675"/>
    <ns4:indication>For the treatment of breast cancer.</ns4:indication>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:0d163419cd19cc76b1254df76b140f49"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_9"/>
    <ns4:substructure>Phenylpropenes</ns4:substructure>
    <ns4:substructure>Phenols and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_4"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1732"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_8"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01118"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:1898"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01030"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00675"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:31fba980b20387c458a3b9eeedde77c7"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00468_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00263_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00472_DB00675"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:10540-29-1"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01012"/>
    <ns4:substructure>Stilbenes</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01132"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_12"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:ebbe785d5fdcc6d09b87401582c9959b"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00582_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01241"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01045"/>
    <ns4:substructure>Styrene Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01124"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:bcdd8c2bc33cc44cdfede0d72251e00f"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00701"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01110"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8be1de9191eec2dec03cd80888b77ff5"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00951"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00675_13"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01151"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00333_DB00675"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00363_DB00675"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c120a2e976eb7e50b5ca43b7be868c2e"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01418"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4d23319cc446077177b9a89dcba1d840"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01369"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00857"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB00682"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00622_DB00675"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C07108"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00544_DB00675"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:373444fdfe80be04c4adb1ebe72b460a"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:136"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01263"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00656_DB00675"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00977">
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Select-1/35"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00776_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00266_DB00977"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA449527"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:G03CA01"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Ethinylestradiol"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00977"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic/estinyl.htm"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00254_DB00977"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <dcterms:description xml:lang="en">A semisynthetic alkylated estradiol with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in oral contraceptives. [PubChem]</dcterms:description>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_8"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:aaba0bccc5169068ea1a9a22dc54db7f"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01603"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Nuvaring"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00682_DB00977"/>
    <ns4:synonym>17 alpha-Ethinylestradiol</ns4:synonym>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00312_DB00977"/>
    <ns4:indication>For treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.</ns4:indication>
    <ns4:biotransformation>Hepatic. Quantitatively, the major metabolic pathway for ethinyl estradiol, both in rats and in humans, is aromatic hydroxylation, as it is for the natural estrogens.</ns4:biotransformation>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_4"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Jolessa"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:78a5bb17aec2925c810857cbb309d563"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00415_DB00977"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Ortho-Cept"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:30d2213687d3bbc5c50fd607eec1d7e6"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01147"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00220_DB00977"/>
    <ns4:substructure>Alcohols and Polyols</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D00554"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00355_DB00977"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Femhrt-1/5"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01628"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Lo-Femenal"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:639f745533a71065f906a72c9e9e6ed7"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Alesse"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Demulen"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_14"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Desogen"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00555_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01045"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01602"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00197_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01223"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:776"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_21"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Cyclen"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Marvelon"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:b2fd883578f6b7ca6f161a63df3fe01a"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Yasminelle"/>
    <ns4:substructure>Steroids and Steroid Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_7"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00400_DB00977"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:5770"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00977_2"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:22ae8eadff4db6c0d61b66b8ec62d2d2"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB06697"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:2e9d2397436d6b2fe7b235a9ce66e8d6"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00930_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00697_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01320"/>
    <ns4:toxicity>Oral, mouse LD&lt;sub&gt;50&lt;/sub&gt;: 1737 mg/kg. Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.</ns4:toxicity>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Junel"/>
    <rdfs:label xml:lang="en">Ethinyl Estradiol [drugbank:DB00977]</rdfs:label>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_5"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00091_DB00977"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_13"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:57-63-6"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_20"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01607"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01061"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01355"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:c59b42b8fe4a3f07e61a5d2eb1157dda"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01351"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01301"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Min-Ovral"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00418_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00485_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00713_DB00977"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Tri-Cyclen-Lo"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Apri"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Lybrel"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00564_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00241_DB00977"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Kariva"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Preven"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:3438834fb5ddeaa35e357c8d20a5ecb0"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00474_DB00977"/>
    <ns4:substructure>Phenanthrenes</ns4:substructure>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Microgestin"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f5a2c060dbdf170bf7617e432f4c60d9"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Seasonale"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00977"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:22c3575a33fa1ede0003984e74e9ebc0"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:9b3511b31a183634709fb2d5976c7868"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4924"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00673_DB00977"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00977_3"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C07534"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Yaz"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Seasonique"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_6"/>
    <ns4:substructure>Naphthalenes</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00615_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01017"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Brevicon"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00794_DB00977"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_15"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00860_DB00977"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:937642f00cd656640c6260e176e9a146"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:699c2a1cfc5cd632638fa87b03f0157c"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00599_DB00977"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8be1de9191eec2dec03cd80888b77ff5"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Loestrin"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00864_DB00977"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f898833a148c62f1a36f29b7bd397c62"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01174"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1588"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00932_DB00977"/>
    <ns4:manufacturer>Schering corp sub schering plough corp</ns4:manufacturer>
    <ns4:category>Estrogens</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_11"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00745_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00759_DB00977"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Femodette"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00503_DB00977"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_9"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01026"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_10"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00273_DB00977"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Triphasil"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1735"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8d44276870e140a7b9bd40131dc9a54c"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:5991"/>
    <ns4:absorption>Rapid and complete absorption follows oral intake of ethinyl estradiol (bioavailability 43%).</ns4:absorption>
    <ns4:protein-binding>97%</ns4:protein-binding>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01353"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01586"/>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:mechanism-of-action>Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. This cascade is initiated by initially binding to the estrogen receptors. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).</ns4:mechanism-of-action>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Evra"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00766_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00301_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00849_DB00977"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_16"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00635_DB00977"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_17"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Aviane"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46508618"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00559_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00607_DB00977"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Ocella"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6141"/>
    <ns4:substructure>Alkynes</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00306_DB00977"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Synphasic"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01352"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00277_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00948_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00754_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00651_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00481_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01201"/>
    <ns4:substructure>Cyclohexenes and Derivatives</ns4:substructure>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Lessina"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:4903"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Triquilar"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00931_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00739_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01125"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:c90fb132fa658ac8d4d4bf246f64a9bb"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_19"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Ovral"/>
    <ns4:substructure>Phenyl Esters</ns4:substructure>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Zarah"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:3f257928c0f820dce127ee8b6c04fee5"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Sronyx"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:3e29f95c9c78ddda1c0228c4367a6130"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00977_1"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:48a11191de26f01206883b656f84660f"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:1284"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Ortho"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Tri-Cyclen"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_12"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01354"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:28231"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01060"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00595_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00532_DB00977"/>
    <ns4:substructure>Phenols and Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00618_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00237_DB00977"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00701_DB00977"/>
    <ns4:half-life>36 +/- 13 hours</ns4:half-life>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01418"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Minestrin-1/20"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Minulet"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Mercilon"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Mircette"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01323"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01606"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:136"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:487cbb24a3c54fb164f15a51ec74d338"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:373444fdfe80be04c4adb1ebe72b460a"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01000"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:pharmacology>Ethinyl estradiol is a synthetic derivative of the natural estrogen estradiol. It is one of two estrogens currently used in oral contraceptive pills. The other, mestranol, is converted to ethinyl estradiol before it is biologically active. Ethinyl estradiol and norethindrone are used together as an oral contraceptive agent.</ns4:pharmacology>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01604"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00319_DB00977"/>
    <ns4:brand>Estinyl</ns4:brand>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Neo-Mens-Tab"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Diane-35"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Ovcon"/>
    <ns4:category>Approved</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00977_DB01303"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00252_DB00977"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Yasmin"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00755_DB00977"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00977_18"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Quasense"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Femodene"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Lutera"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00539">
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00344_DB00539"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_7"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/toremifene.html"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00933"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L02BA02"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00204_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00468_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00714"/>
    <ns4:substructure>Alkanes and Alkenes</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01599"/>
    <ns4:substructure>Phenyl Esters</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00218_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00104_DB00539"/>
    <rdfs:label xml:lang="en">Toremifene [drugbank:DB00539]</rdfs:label>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00489_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00875"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00540"/>
    <ns4:substructure>Alkyl Halides</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01195"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_18"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00458_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00472_DB00539"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:89778-26-7"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01118"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:4696949"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00270_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00738"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00604"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_14"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB06697"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00243_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00934"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00615"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01044"/>
    <dcterms:description xml:lang="en">A first generation nonsteroidal selective estrogen receptor modulator (SERM) that is structurally related to tamoxifen. Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. [PubChem]</dcterms:description>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_5"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_16"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB06708"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01211"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00321_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00333_DB00539"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00808"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB04844"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01035"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Toremifene"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_8"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00199_DB00539"/>
    <ns4:mechanism-of-action>Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, in other words, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor. Toremifene may also inhibit tumor growth through other mechanisms, such as induction of apoptosis, regulation of oncogene expression, and growth factors.</ns4:mechanism-of-action>
    <ns4:substructure>Anisoles</ns4:substructure>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00196_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00408_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00106_DB00539"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:substructure>Phenylpropenes</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_15"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01142"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01218"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00477_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01242"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46506087"/>
    <ns4:substructure>Aliphatic and Aryl Amines</ns4:substructure>
    <ns4:protein-binding>Toremifen is primarily bound to albumin (92%), 2% bound to α1-acid glycoprotein, and 6% bound to  β1-globulin in the serum.</ns4:protein-binding>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA451731"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01184"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_6"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:657375d8bc233632f31fc1c077032139"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_3"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00582"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_10"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00246_DB00539"/>
    <ns4:half-life>5 days</ns4:half-life>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00976"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:136"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:2275722"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01137"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00872"/>
    <ns4:indication>For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.</ns4:indication>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_13"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:3005573"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00280_DB00539"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:biotransformation>Hepatic. Mainly by CYP3A4 to N-demethyltoremifene, which exhibits antiestrogenic effects but has weak antitumor potency in vivo.</ns4:biotransformation>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01224"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00726"/>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01059"/>
    <ns4:substructure>Phenols and Derivatives</ns4:substructure>
    <ns4:route-of-elimination>Toremifene is extensively metabolized, principally by CYP3A4 to N-demethyltoremifene, which is also antiestrogenic but with weak in vivo antitumor potency.</ns4:route-of-elimination>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c46fd09cd1db2f8a83e010e325a2c70c"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00734"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:11399-005-30"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_17"/>
    <ns4:volume-of-distribution>* 580 L</ns4:volume-of-distribution>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00543"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00908"/>
    <ns4:absorption>Well absorbed</ns4:absorption>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01624"/>
    <ns4:pharmacology>Toremifene is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer. Toremifene is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Toremifene inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, Toremifene appears to exert its antitumor effects by binding the estrogen receptors. In cytosols derived from human breast adenocarcinomas, Toremifene competes with estradiol for estrogen receptor protein.</ns4:pharmacology>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01100"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1588"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00539"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01169"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01259"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00679"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6024"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_2"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01623"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00502_DB00539"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_12"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:9635"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB02546"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C08166"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00556"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00539_1"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00864"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01151"/>
    <ns4:substructure>Stilbenes</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_9"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00308_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01208"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01268"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01045"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_11"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic2/toremifene.htm"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB00757"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01254"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01182"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4200"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00358_DB00539"/>
    <ns4:substructure>Isoprenes</ns4:substructure>
    <ns4:category>Approved</ns4:category>
    <ns4:manufacturer>Gtx inc</ns4:manufacturer>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00539_4"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB04868"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:brand>Acapodene</ns4:brand>
    <ns4:substructure>Styrene Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00529_DB00539"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00450_DB00539"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00380">
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_15"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:817"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/dexrazoxane.html"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_9"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00380"/>
    <ns4:volume-of-distribution>* 9 to 22.6 L/m^2</ns4:volume-of-distribution>
    <ns4:substructure>Aliphatic and Aryl Amines</ns4:substructure>
    <ns4:substructure>Piperazines</ns4:substructure>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:65d8cbfc70a71735aba8f974ab1c5a43"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_4"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:64479"/>
    <ns4:substructure>Carboxylic Acids and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_16"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:38423-110-01"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_6"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_5"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_14"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic2/dexrazoxane.htm"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_20"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00380_2"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <dcterms:description xml:lang="en">An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem]
The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.</dcterms:description>
    <ns4:substructure>Carboxamides and Derivatives</ns4:substructure>
    <ns4:substructure>Amino Ketones</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:24584-09-6"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:V03AF02"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:5242901"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_11"/>
    <ns4:brand>Cardioxane</ns4:brand>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00380"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:bd81bad34efcab1f213f97775d3d5824"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_8"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00380_1"/>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:4192"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:abcf0f981387f9e56f1d9ddcc8fd67cd"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA449259"/>
    <ns4:category>Approved</ns4:category>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:850c65d9c13dfb84947211823a183dba"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Dexrazoxane"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_12"/>
    <ns4:biotransformation>Dexrazoxane is hydrolysed by the enzyme dihydropyrimidine amidohydrolase in the liver and kidney to active metabolites that are capable of binding to metal ions.</ns4:biotransformation>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:9d5e562a23555c1c206c9bb0a13cd884"/>
    <ns4:pharmacology>Dexrazoxane is a cardioprotective agent for use in conjunction with doxorubicin indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose. Patients receiving anthracycline-derivative antineoplastic agents may experience three types of cardiotoxicity: acute transient type; chronic, subacute type (related to cumulative dose and has a more indolent onset later on); and a late-onset type that manifests years after therapy, mainly in patients that have been exposed to the drug as a child. Although the exact mechanism of anthracycline-induced cardiotoxicity is not known, it has shown to exert a variety of actions that may result in the development of cardiotoxicity. In animals, anthracyclines cause a selective inhibition of cardiac muscle gene expression for α-actin, troponin, myosin light-chain 2, and the M isoform of creatine kinase. This may lead to myofibrillar loss associated with anthracycline-induced cardiotoxicity. Anthracyclines may also cause myocyte damage via calcium overload, altered myocardial adrenergic function, release of vasoactive amines, and proinflammatory cytokines. Furthermore, it has been suggested that the main cause of anthracycline-induced cardiotoxicity is associated with free-radical damage to DNA. The drugs intercalate DNA, chelate metal ions to produce drug-metal complexes, and generate superoxide radicals via oxidation-reduction reactions. Anthracyclines also contain a quinone structure that can undergo reduction via NADPH-dependent reactions to produce a semiquinone free radical that initiates a cascade of superoxide and hydroxide radical generation. Chelation of metal ions, particularly iron, by anthracyclines results in an anthracycline-metal complex that catalyzes the generation of reactive oxygen free radicals. This complex is a powerful oxidant that can initiate lipid peroxidation in the absence of oxygen free radicals. The toxicity induced by antrhacyclines may be exacerbated in cardiac cells, as these cells do not possess sufficient amounts of certain enzymes (e.g., superoxide dismutase, catalase, glutathione peroxidase) involved in detoxifying free radicals and protecting the cells from subsequent damage.</ns4:pharmacology>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:6727253"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pdb:CDX"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8a7d4af18b64df6b29be9483344342ef"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:19bcb6c73e1414cc4ab588948e9c515e"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46505982"/>
    <ns4:protein-binding>Very low (&lt; 2%)</ns4:protein-binding>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_18"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_17"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_10"/>
    <ns4:route-of-elimination>Urinary excretion plays an important role in the elimination of dexrazoxane. Forty-two percent of the 500 mg/m2 dose of dexrazoxane was excreted in the urine.</ns4:route-of-elimination>
    <ns4:mechanism-of-action>The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane (a prodrug) is converted intracellularly to a ring-opened bidentate chelating agent that chelates to free iron and interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. It should be noted that dexrazoxane may also be protective through its inhibitory effect on topoisomerase II.</ns4:mechanism-of-action>
    <ns4:toxicity>Intraperitoneal, mouse LD&lt;sub&gt;10&lt;/sub&gt; = 500 mg/kg. Intravenous, dog LD&lt;sub&gt;10&lt;/sub&gt; = 2 gm/kg.</ns4:toxicity>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:13e8d5e28fb251ec51bdad66d6544621"/>
    <ns4:synonym>Desrazoxane</ns4:synonym>
    <ns4:category>Small molecule</ns4:category>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:02f2f00d056c05b20f4f521d91edeeae"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_19"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2153440"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:3dfe7a9b1d36defe7e70e10286a17ee2"/>
    <ns4:indication>For reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m^2 and would benefit from continued doxorubicin therapy. Also approved for the treatment of extravasation from intravenous anthracyclines.</ns4:indication>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:50223"/>
    <ns4:absorption>IV administration results in complete bioavailability.</ns4:absorption>
    <rdfs:label xml:lang="en">Dexrazoxane [drugbank:DB00380]</rdfs:label>
    <ns4:manufacturer>Bedford laboratories div ben venue laboratories inc</ns4:manufacturer>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:71384"/>
    <ns4:half-life>2.5 hours</ns4:half-life>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_3"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_7"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00380_13"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00894">
    <ns4:protein-binding>~85%</ns4:protein-binding>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:substructure>Thromboxanes</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_6"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_12"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:496a00848a8fffb1273901aeb7ba3ce7"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_16"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_9"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_17"/>
    <ns4:substructure>Lactones</ns4:substructure>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic2/testolactone.htm"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00894_2"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_5"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00682_DB00894"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46508076"/>
    <ns4:category>Antineoplastic Agents, Hormonal</ns4:category>
    <ns4:substructure>Alkanes and Alkenes</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA451626"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_14"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3811"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_11"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C02197"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:9460"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00091_DB00894"/>
    <ns4:absorption>Testolactone is well absorbed from the gastrointestinal tract.</ns4:absorption>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:brand>Fludestrin</ns4:brand>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_7"/>
    <ns4:biotransformation>Hepatic. Metabolized to several derivatives in the liver, all of which preserve the lactone D-ring.</ns4:biotransformation>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:category>Approved</ns4:category>
    <ns4:pharmacology>Testolactone is a synthetic anti-neoplastic agent that is structurally distinct from the androgen steroid nucleus in possessing a six-membered lactone ring in place of the usual five-membered carbocyclic D-ring. Despite some similarity to testosterone, testolactone has no in vivo androgenic effect. No other hormonal effects have been reported in clinical studies in patients receiving testolactone.</ns4:pharmacology>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:968-93-4"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_10"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:substructure>Pyrans</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:67a442d044446c216d98f4d5e5378c53"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_4"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00894_DB01418"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00894"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/testolactone.html"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_18"/>
    <ns4:manufacturer>Bristol myers squibb</ns4:manufacturer>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D00153"/>
    <ns4:substructure>Carboxylic Acids and Derivatives</ns4:substructure>
    <ns4:synonym>Testolactona [INN-Spanish]</ns4:synonym>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_8"/>
    <ns4:substructure>Acetates</ns4:substructure>
    <ns4:mechanism-of-action>Although the precise mechanism by which testolactone produces its clinical antineoplastic effects has not been established, its principal action is reported to be inhibition of steroid aromatase activity and consequent reduction in estrone synthesis from adrenal androstenedione, the major source of estrogen in postmenopausal women. Based on in vitro studies, the aromatase inhibition may be noncompetitive and irreversible. This phenomenon may account for the persistence of testolactone's effect on estrogen synthesis after drug withdrawal.</ns4:mechanism-of-action>
    <ns4:substructure>Ketones</ns4:substructure>
    <ns4:category>Small molecule</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_13"/>
    <ns4:indication>For palliative treatment of advanced breast cancer in postmenopausal women.</ns4:indication>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:13769"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00894"/>
    <ns4:route-of-elimination>No clinical effects in humans of testolactone on adrenal function have been reported; however, one study noted an increase in urinary excretion of 17-ketosteroids in most of the patients treated with 150 mg/day orally. It is metabolized to several derivatives in the liver, all of which preserve the lactone D-ring. These metabolites, as well as some unmetabolized drug, are excreted in the urine.</ns4:route-of-elimination>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00894_1"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_3"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0003-0690-50"/>
    <ns4:substructure>Steroids and Steroid Derivatives</ns4:substructure>
    <ns4:toxicity>Oral LD&lt;sub&gt;50&lt;/sub&gt;s in mouse and dog are 1630 mg/kg and 593-926 mg/kg, respectively.</ns4:toxicity>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:3b66b3f52cd8a958f6e26f04b55096b6"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_19"/>
    <rdfs:label xml:lang="en">Testolactone [drugbank:DB00894]</rdfs:label>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00894_15"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:13172"/>
    <dcterms:description xml:lang="en">An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer. [PubChem]</dcterms:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB01101">
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01101"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:3936"/>
    <ns4:absorption>Readily absorbed through the GI tract (~70%)</ns4:absorption>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_6"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4604"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00532_DB01101"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01101_DB01320"/>
    <ns4:substructure>Glycerol and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_15"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:1327358"/>
    <ns4:synonym>R340</ns4:synonym>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB01101_1"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_18"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB01101_2"/>
    <dcterms:description xml:lang="en">Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.</dcterms:description>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_10"/>
    <ns4:route-of-elimination>Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine. Fecal excretion is minimal (2.6%). The major metabolite excreted in urine is FBAL which represents 57% of the administered dose.About 3% of the administered dose is excreted in urine as unchanged drug.</ns4:route-of-elimination>
    <ns4:protein-binding>&lt; 60% (mainly albumin)</ns4:protein-binding>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_13"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:31348"/>
    <ns4:substructure>Alcohols and Polyols</ns4:substructure>
    <ns4:substructure>Aryl Halides</ns4:substructure>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:359"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8be1de9191eec2dec03cd80888b77ff5"/>
    <ns4:food-interaction>Take 12 hours apart, within 30 minutes of the end of breakfast and dinner to reduce nausea.</ns4:food-interaction>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_7"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00682_DB01101"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_9"/>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_16"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_12"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:12cb0d72837fbf708acf564a0ee3f8a7"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C12650"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00214_DB01101"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L01BC06"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:874"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/capecitabine.html"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA448771"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_3"/>
    <ns4:substructure>Furans</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00252_DB01101"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:487cbb24a3c54fb164f15a51ec74d338"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:1302"/>
    <ns4:brand>Xeloda</ns4:brand>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2238454"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:6075"/>
    <ns4:mechanism-of-action>Capecitabine is a prodrug that is selectively tumour-activated to its cytotoxic moiety, fluorouracil, by thymidine phosphorylase, an enzyme found in higher concentrations in many tumors compared to normal tissues or plasma. Fluorouracil is further metabolized to two active metabolites, 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP), within normal and tumour cells. These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deaxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, therefore a deficiency of this compound can inhibit cell division. Secondly, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis through the production of fraudulent RNA.</ns4:mechanism-of-action>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4211"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB01101"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:4966891"/>
    <ns4:substructure>Carbamates and Derivatives</ns4:substructure>
    <ns4:substructure>Pyrimidines and Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01101_DB01124"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00675_DB01101"/>
    <ns4:indication>For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.</ns4:indication>
    <ns4:half-life>45-60 minutes for capecitabine and its metabolites.</ns4:half-life>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Capecitabine"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB01101"/>
    <ns4:biotransformation>Metabolized by thymidine phosphorylase to fluoruracil.</ns4:biotransformation>
    <ns4:substructure>Cyanamides</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D01223"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_4"/>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01101_DB01125"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:54916"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:78cd24aeefc8fd990fd5f3c97b839e04"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00266_DB01101"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4757"/>
    <ns4:category>Approved</ns4:category>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic3/capecitabine.htm"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_11"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_8"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_17"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:154361-50-9"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:5472949"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_14"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00549_DB01101"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2103324"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:pharmacology>Capecitabine is a fluoropyrimidine carbamate with antineoplastic activity indicated for the treatment of metastatic breast cancer and colon cancer. It is an orally administered systemic prodrug that has little pharmacologic activity until it is converted to fluorouracil by enzymes that are expressed in higher concentrations in many tumors. Fluorouracil it then metabolized both normal and tumor cells to 5-fluoro-2′-deoxyuridine 5′-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP).</ns4:pharmacology>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_5"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0004-1100-20"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46508686"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00582_DB01101"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_19"/>
    <rdfs:label xml:lang="en">Capecitabine [drugbank:DB01101]</rdfs:label>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:5f4df6d410318c0872a704ea3ca60a82"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01101_DB01418"/>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:manufacturer>Hoffmann la roche inc</ns4:manufacturer>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00754_DB01101"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00440_DB01101"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:60953"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01101_20"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00441">
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic/gemcitab.htm"/>
    <dcterms:description xml:lang="en">Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar® by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as new nucleosides cannot be attached to the "faulty" nucleoside, resulting in apoptosis (cellular "suicide").
Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. It is being investigated for use in oesophageal cancer, and is used experimentally in lymphomas and various other tumor types.</dcterms:description>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_6"/>
    <ns4:half-life>Short infusions ranged from 32 to 94 minutes, and the value for long infusions vary from 245 to 638 minutes, depending on age and gender.</ns4:half-life>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:95058-81-4"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00006_DB00441"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00441_DB00682"/>
    <ns4:substructure>Pyrimidines and Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00441_DB01229"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:360"/>
    <ns4:biotransformation>Transformed via nucleoside kinases to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate. Can also undergo deamination via cytidine deaminase to an inactive uracil metabolite (dFdU).</ns4:biotransformation>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0002-7501-01"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_5"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:874"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_9"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_18"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_20"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_19"/>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_8"/>
    <rdfs:label xml:lang="en">Gemcitabine [drugbank:DB00441]</rdfs:label>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_15"/>
    <ns4:protein-binding>Plasma protein binding is negligible (&lt;10%)</ns4:protein-binding>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2230309"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_17"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00441_2"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L01BC05"/>
    <ns4:brand>DDFC</ns4:brand>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00441_DB06287"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:13e8d5e28fb251ec51bdad66d6544621"/>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00266_DB00441"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:702"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1588"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_13"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_3"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4773"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_16"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00441"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_11"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C07650"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:bd7a0db6cf1906a9aa9e067d54860e92"/>
    <ns4:volume-of-distribution>* 50 L/m^2 [infusions lasting &lt;70 minutes]
* 370 L/m^2 [long infusions]</ns4:volume-of-distribution>
    <ns4:toxicity>Myelosuppression, paresthesias, and severe rash were the principal toxicities, LD&lt;sub&gt;50&lt;/sub&gt;=500 mg/kg (orally in mice and rats)</ns4:toxicity>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00441_DB01418"/>
    <ns4:substructure>Glycerol and Derivatives</ns4:substructure>
    <ns4:pharmacology>Gemcitabine is an antineoplastic anti-metabolite. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (or DNA synthesis phase of the cell cycle), stopping normal development and division. Gemcitabine blocks an enzyme which converts the cytosine nucleotide into the deoxy derivative. In addition, DNA synthesis is further inhibited because Gemcitabine blocks the incorporation of the thymidine nucleotide into the DNA strand.</ns4:pharmacology>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46506425"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:5464826"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00441"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Gemcitabine"/>
    <ns4:indication>For the first-line treatment of patients with metastatic breast cancer, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer and as first-line treatment for patients with adenocarcinoma of the pancreas.</ns4:indication>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4211"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pdb:GEO"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_10"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:manufacturer>Teva parenteral medicines inc</ns4:manufacturer>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_7"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:eae7e64482e6b7ee790e23f5ceb8bfd5"/>
    <ns4:substructure>Furans</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00441"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:2222"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:4808614"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:359"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00441_DB01125"/>
    <ns4:substructure>Aliphatic and Aryl Amines</ns4:substructure>
    <ns4:category>Approved</ns4:category>
    <ns4:substructure>Alcohols and Polyols</ns4:substructure>
    <ns4:absorption>100%</ns4:absorption>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6148"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D02368"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:substructure>Cyanamides</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:54753"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:112023f204f52ead0033d2d0bf764a36"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_14"/>
    <ns4:mechanism-of-action>Gemcitabine inhibits thymidylate synthetase, leading to inhibition of DNA synthesis and cell death. Gemcitabine is a prodrug so activity occurs as a result of intracellular conversion to two active metabolites, gemcitabine diphosphate and gemcitabine triphosphate by deoxycitidine kinase. Gemcitabine diphosphate also inhibits ribonucleotide reductase, the enzyme responsible for catalyzing synthesis of deoxynucleoside triphosphates required for DNA synthesis. Finally, Gemcitabine triphosphate (diflurorodeoxycytidine triphosphate) competes with endogenous deoxynucleoside triphosphates for incorporation into DNA.</ns4:mechanism-of-action>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:175901"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_12"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00441_4"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00441_1"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8cb85c0619090c89d296c9568517a84b"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/gemcitabine.html"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:60750"/>
    <ns4:substructure>Alkyl Halides</ns4:substructure>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB01616">
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_1"/>
    <ns4:synonym>Alverina [inn-spanish]</ns4:synonym>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:320"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:4e9fbe7a730380e235f0fa60c66eb910"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_17"/>
    <ns4:category>Approved</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_12"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_2"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_3"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_4"/>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00674_DB01616"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00843_DB01616"/>
    <ns4:biotransformation>Rapidly converted to its primary active metabolite, which is then further converted to two secondary metabolites. </ns4:biotransformation>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <rdfs:label xml:lang="en">Alverine [drugbank:DB01616]</rdfs:label>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D07440"/>
    <ns4:pharmacology>Alverine is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasms which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. Diverticular disease is a condition in which small pouches form in the gut lining. These pouches can trap particles of food and become inflamed and painful. In irritable bowel syndrome the normal activity of the gut muscle is lost. The muscle spasms result in symptoms such as heartburn, abdominal pain and bloating, constipation or diarrhoea. By relaxing the gut muscle, alverine citrate relieves the symptoms of this condition. Alverine also relaxes the smooth muscle in the womb (uterus). It is therefore also used to treat painful menstruation, which is caused by muscle spasms in the uterus (dysmenorrhea).</ns4:pharmacology>
    <ns4:category>Small molecule</ns4:category>
    <ns4:toxicity>Can produce hypotension and atropine-like toxic effects. Fatality has occurred following overdose with very high doses.</ns4:toxicity>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_8"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:3550"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:brand>Audmonal</ns4:brand>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:518413"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:150-59-4"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_15"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_16"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:A03AX08"/>
    <dcterms:description xml:lang="en">Alverine is a smooth muscle relaxant. Smooth muscle is a type of muscle that is not under voluntary control; it is the muscle present in places such as the gut and uterus. Alverine acts directly on the muscle in the gut, causing it to relax. This prevents the muscle spasms which occur in the gut in conditions such as irritable bowel syndrome and diverticular disease. It is used to  relieve cramps or spasms of the stomach and intestines. It is also useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain. Alverine is formulated as the citrate salt (5982-87-6).</dcterms:description>
    <ns4:substructure>Aliphatic and Aryl Amines</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46506981"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Alverine"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB01616"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_5"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_6"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_10"/>
    <ns4:indication>Used to relieve cramps or spasms of the stomach and intestines. It is also useful in treating irritable bowel syndrome (IBS) and similar conditions. It can also be used to help relieve period pain. Alverine citrate is also under investigation to increase the cytotoxic effects of the proteasome inhibitor MG132 on breast cancer cells.</ns4:indication>
    <ns4:half-life>The plasma half-life averages 0.8 hours for alverine and 5.7 hours for the active primary metabolite.</ns4:half-life>
    <ns4:category>Antispasmodics</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_14"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_9"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_13"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_11"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:3678"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB01616"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01616_7"/>
    <ns4:substructure>Phenylpropylamines</ns4:substructure>
    <ns4:route-of-elimination>High renal clearance of all metabolites indicating that they are eliminated by active renal secretion.</ns4:route-of-elimination>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB06710">
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:toxicity>Side effects include amnesia, anxiety, discolored hair, dizziness, dry skin, hirsutism, hostility, impaired urination, paresthesia, penis disorder, peripheral edema, sweating, and vasodilation.</ns4:toxicity>
    <ns4:manufacturer>Valeant pharmaceuticals international</ns4:manufacturer>
    <ns4:category>Small molecule</ns4:category>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D00408"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6139"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_3"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_13"/>
    <ns4:brand>Android</ns4:brand>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_7"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_14"/>
    <ns4:indication>Methyltestosterone is an anabolic steroid hormone used to treat men with a testosterone deficiency. It is also used in women to treat breast cancer, breast pain, swelling due to pregnancy, and with the addition of estrogen it can treat symptoms of menopause.</ns4:indication>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_11"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_8"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_17"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_5"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Methyltestosterone"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_1"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C07198"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:G03BA02"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB06710"/>
    <ns4:absorption>The methyl group aids to increase oral bioavailability.</ns4:absorption>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_16"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_4"/>
    <ns4:category>Anabolic Agents</ns4:category>
    <ns4:mechanism-of-action>The effects of testosterone in humans and other vertebrates occur by way of two main mechanisms: by activation of the androgen receptor (directly or as DHT), and by conversion to estradiol and activation of certain estrogen receptors. Free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5&amp;alpha;-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5&amp;alpha;-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.</ns4:mechanism-of-action>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:category>Approved</ns4:category>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB06710"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_2"/>
    <ns4:route-of-elimination>90% urine / 10% feces</ns4:route-of-elimination>
    <ns4:protein-binding>40% of testosterone in plasma is bound to sex hormone-binding globulin and 2% remains unbound and the rest is bound to albumin and other proteins.</ns4:protein-binding>
    <ns4:half-life>6-8 hours</ns4:half-life>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:146"/>
    <ns4:synonym>17-methyltestosterone</ns4:synonym>
    <ns4:biotransformation>Hepatic.
Testosterone is metabolized to 17-keto steroids through two different pathways. The major active metabolites are estradiol and dihydrotestosterone (DHT).</ns4:biotransformation>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_12"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:58-18-4"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:3811"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6030"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_10"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_9"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_6"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:27436"/>
    <rdfs:label xml:lang="en">Methyltestosterone [drugbank:DB06710]</rdfs:label>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6142"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06710_15"/>
    <ns4:pharmacology>Testosterone is a steroid hormone from the androgen group. Testosterone is primarily secreted from the testes of males. In females, it is produced in the ovaries, adrenal glands and by conversion of adrostenedione in the periphery. It is the principal male sex hormone and an anabolic steroid. In both males and females, it plays key roles in health and well-being. Examples include enhanced libido, energy, immune function, and protection against osteoporosis. On average, the adult male body produces about twenty times the amount of testosterone than an adult female's body does.</ns4:pharmacology>
    <dcterms:description xml:lang="en">A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US.</dcterms:description>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00445">
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA449476"/>
    <ns4:protein-binding>77%</ns4:protein-binding>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2069512"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_20"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_19"/>
    <ns4:substructure>Anthracyclines</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_13"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:substructure>Pyrans</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:18ff47f84d5428f7ac02e7d0e70ac2a9"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:72310832bf027a32c1d651210362d0cd"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:012ba3ae3c89f3f5806cdccd536efe32"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00445_1"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:a1571d54214cbf7a935473e888ab5f6a"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:02f2f00d056c05b20f4f521d91edeeae"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic2/epirub.htm"/>
    <ns4:category>Approved</ns4:category>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L01DB03"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:substructure>Cyclohexenes and Derivatives</ns4:substructure>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_8"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:464e0508f3faa406e1fc1d033901558c"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_3"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:b8692eb033bb1d6f58f07661537114b7"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:2458e982109b40327f8f0797b4025ae0"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_10"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:aa821d692739e5f095f580927ac9fbb6"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:6b64c016d33c6c53ec701808f4ced7cf"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB00445"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_18"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:fbe5ec4e8a00c96761708182bb760cd3"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:41867"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:b9db2fe4cd4014a788856441f9d848b8"/>
    <ns4:half-life>Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively</ns4:half-life>
    <ns4:substructure>Phenyl Esters</ns4:substructure>
    <ns4:substructure>Benzyl Alcohols and Derivatives</ns4:substructure>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6178"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00445_DB00501"/>
    <ns4:substructure>Anthracenes</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:ad6003e1d26bc136c0ac8494d6d39915"/>
    <ns4:biotransformation>Extensively and rapidly metabolized in the liver. Epirubicin is also metabolized by other organs and cells, including red blood cells. The four main metabolic routes are: (1) reduction of the C-13 keto-group with the formation of the 13(S)-dihydro derivative, epirubicinol; (2) conjugation of both the unchanged drug and epirubicinol with glucuronic acid; (3) loss of the amino sugar moiety through a hydrolytic process with the formation of the doxorubicin and doxorubicinol aglycones; and (4) loss of the amino sugar moiety through a redox process with the formation of the 7-deoxy-doxorubicin aglycone and 7-deoxy-doxorubicinol aglycone. Epirubicinol exhibits in vitro cytoxic activity (~10% that of epirubicin), but it is unlikely to reach sufficient concentrations in vivo to produce cytotoxic effects. </ns4:biotransformation>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:588"/>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:indication>For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.</ns4:indication>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00445"/>
    <ns4:pharmacology>Epirubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Epirubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Epirubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific.</ns4:pharmacology>
    <ns4:substructure>Alcohols and Polyols</ns4:substructure>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00445_2"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:d09cb0a717a7fc584cb28ad36078bbe5"/>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_17"/>
    <ns4:substructure>Phenols and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_9"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:56420-45-2"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_5"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:874"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:817"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:fd74c0323621ae5c390f3166a448d2ee"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46507282"/>
    <ns4:toxicity>bone marrow aplasia, grade 4 mucositis, and gastrointestinal bleeding</ns4:toxicity>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C11230"/>
    <ns4:mechanism-of-action>Epirubicin has antimitotic and cytotoxic activity. It inhibits nucleic acid (DNA and RNA) and protein synthesis through a number of proposed mechanisms of action: Epirubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. It also interferes with DNA replication and transcription by inhibiting DNA helicase activity.</ns4:mechanism-of-action>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_14"/>
    <ns4:food-interaction>Liberal fluid intake to increase urine output and help the excretion of uric acid.</ns4:food-interaction>
    <ns4:substructure>Ketones</ns4:substructure>
    <rdfs:label xml:lang="en">Epirubicin [drugbank:DB00445]</rdfs:label>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Epirubicin"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:38201"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_12"/>
    <ns4:substructure>Amino Alcohols</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:61703-347-35"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_7"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f5a2c060dbdf170bf7617e432f4c60d9"/>
    <ns4:substructure>Anthraquinones</ns4:substructure>
    <ns4:manufacturer>Pfizer inc</ns4:manufacturer>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:9d5e562a23555c1c206c9bb0a13cd884"/>
    <ns4:substructure>Aliphatic and Aryl Amines</ns4:substructure>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:absorption>100%</ns4:absorption>
    <ns4:route-of-elimination>Epirubicin and its major metabolites are eliminated through biliary excretion and, to a lesser extent, by urinary excretion.</ns4:route-of-elimination>
    <ns4:volume-of-distribution>* 21 ± 2 L/kg [60 mg/m2 Dose]
* 27 ± 11 L/kg [75 mg/m2 Dose]
* 23 ± 7 L/kg [120 mg/m2 Dose]
* 21 ± 7 L/kg [150 mg/m2 Dose]</ns4:volume-of-distribution>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:458cb389b35191b4cc48f99b671097f7"/>
    <ns4:substructure>Naphthoquinones</ns4:substructure>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:723"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_6"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_16"/>
    <ns4:brand>4'-Epiadriamycin</ns4:brand>
    <ns4:substructure>Benzoyl Derivatives</ns4:substructure>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/epirubicin.html"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:substructure>Naphthalenes</ns4:substructure>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00445"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:4b5c0bb3f1d90576a038a3f972025295"/>
    <ns4:substructure>Anisoles</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:47898"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_11"/>
    <ns4:substructure>Acetals and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_4"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:862"/>
    <ns4:substructure>Benzoquinones</ns4:substructure>
    <ns4:category>Small molecule</ns4:category>
    <dcterms:description xml:lang="en">An anthracycline which is the 4&amp;#39;-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. [PubChem]</dcterms:description>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:7e669d0163eb45b4071657bae4b22c09"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00445_15"/>
    <ns4:substructure>Hydroquinones</ns4:substructure>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00351">
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:5a3cd831b797cc462742bba13da7d6a0"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_19"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_12"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB00400"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB00418"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:a0f8cf3c320eb4d15df4d4a2deb6cbb7"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1588"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:G03AC05"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:611995a47511d7a47be091b9fb249563"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:67fececb8066f6887d0f235b491e287e"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_3"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0054-3542-58"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:ebbe785d5fdcc6d09b87401582c9959b"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8130e0f80af50eaf75a28304982a0e74"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:b91976023bcbe18cb7a7d3d79044e966"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:dd6af06f38d938851b3cb658468f6422"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00306_DB00351"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_8"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:0c5a104749aab7f48bb51d4fac8e939f"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:22c3575a33fa1ede0003984e74e9ebc0"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2223112"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_14"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:84410708499ca58b95472b7cca345509"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:acfcf2804dd1b9542bf57489b4f38ae9"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB01174"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:51be03935976ca97c81961776ad4016c"/>
    <dcterms:description xml:lang="en">17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer. [PubChem]</dcterms:description>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00351"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_13"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4d23319cc446077177b9a89dcba1d840"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00351"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/megestrol.html"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:3562-63-8"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8be1de9191eec2dec03cd80888b77ff5"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_20"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8d44276870e140a7b9bd40131dc9a54c"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:ece2b3ad9e15042c78b0330d17614bb8"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00351_2"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:bcdd8c2bc33cc44cdfede0d72251e00f"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:614"/>
    <ns4:category>Antineoplastic Agents, Hormonal</ns4:category>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:ea965d6b3adeb99bb4db35d48574971e"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c0b36bcdbdbd6a3cba0bde8bf6364b8c"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8b94de7669b3b2ef38c3f4637a78f8a8"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB00794"/>
    <rdfs:label xml:lang="en">Megestrol [drugbank:DB00351]</rdfs:label>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:65a741c23ae83fc94a73f0e4d97a5f3c"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8a7d4af18b64df6b29be9483344342ef"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f7d54d2b694b02e59c15962ab1cf2b1b"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_17"/>
    <ns4:category>Approved</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB01320"/>
    <ns4:indication>For the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.</ns4:indication>
    <ns4:brand>Magestin</ns4:brand>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4d1948e403f641887747ddfdd191e9dd"/>
    <ns4:route-of-elimination>The major route of drug elimination in humans is urine. 
Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces.</ns4:route-of-elimination>
    <ns4:absorption>Variable, but well absorbed orally.</ns4:absorption>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_11"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:78be668105544a8b0568e3522b6d4112"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:7eb66565e38916d4783701fcfd3e57b6"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:7bee213832292f1d1685c7e46f011925"/>
    <ns4:manufacturer>Bristol myers squibb</ns4:manufacturer>
    <ns4:mechanism-of-action>The precise mechanism by which megestrol acetate produces effects in anorexia and cachexia is unknown at the present time, but its progestin antitumour activity may involve suppression of luteinizing hormone by inhibition of pituitary function. Studies also suggest that the megestrol's weight gain effect is related to its appetite-stimulant or metabolic effects rather than its glucocorticoid-like effects or the production of edema. It has also been suggested that megestrol may alter metabolic pathyways via interferences with the production or action of mediators such as cachectin, a hormone that inhibits adipocyte lipogenic enzymes. </ns4:mechanism-of-action>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:6722"/>
    <ns4:pharmacology>Megestrol is a synthetic progestin and has the same physiologic effects as natural progesterone. These effects include induction of secretory changes in the endometrium, increase in basal body temperature, pituitary inhibition, and production of withdrawal bleeding in the presence of estrogen. Mestrogel has slight glucocorticoid activity and very slight mineralocorticoid activity. This drug has no estrogenic, androgenic, or anabolic activity. The precise mechanism of megestrol&amp;rsquo;s antianorexic and anticachetic effects is unknown. Initially developed as a contraceptive, it was first evaluated in breast cancer treatment in 1967.</ns4:pharmacology>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:1c02d09e312c9e902a8f4dab816267aa"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00241_DB00351"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_18"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic4/megace_es.htm"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB01354"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:58b478a96ebe9f5b309f89de94cbb2a7"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:7101576"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:871"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB00474"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_10"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00252_DB00351"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f5a2c060dbdf170bf7617e432f4c60d9"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB01355"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:e53bf1ff3465b41d0ed6bc2da10bbb1c"/>
    <ns4:biotransformation>Primarily hepatic. Megestrol metabolites which were identified in urine constituted 5% to 8% of the dose administered. Respiratory excretion as labeled carbon dioxide and fat storage may have accounted for at least part of the radioactivity not found in urine and feces. No active metabolites have been identified.</ns4:biotransformation>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C07120"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:fa1194a61cb470efd26d794228b8359d"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB00532"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:22ae8eadff4db6c0d61b66b8ec62d2d2"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:0a3e0f1db39b21b20ac772b15200ada3"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:db4cc021c81610f377dcc059b0740d1e"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_5"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:bbed48def53ae5b3f5b5cbbce1c6ffba"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00237_DB00351"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f4dd7e2d92d602e0a5c5d3a9d909787f"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:487cbb24a3c54fb164f15a51ec74d338"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:48f125d66776ef9d2feb4111bdcae396"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:de5d3bd460be252fe35f438d64ddadaf"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB01352"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_9"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_16"/>
    <ns4:half-life>34 hours</ns4:half-life>
    <ns4:synonym>Megestrol Acetate</ns4:synonym>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00312_DB00351"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_7"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:713b6d879e78492df23bef8dd4983336"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:457f627df11d5a3afb23acb5e1087bc9"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Megestrol"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:527d934b6e6017671c286c817eb931ba"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB01353"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_6"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB01351"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00351_1"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:e3f78f2936cd81a092dd74c785f8381f"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:toxicity>No serious unexpected side effects have resulted from studies involving megestrol acetate oral suspension administered in dosages as high as 1200 mg/day. Treatment with megestrol acetate, an orexigenic agent, has also resulted in iatrogenic adrenal suppression. The mechanism is presumably related to the glucocorticoid properties of megestrol acetate [PMID: 12872362].</ns4:toxicity>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB00849"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00351_DB00754"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_15"/>
    <ns4:food-interaction>Take with food.</ns4:food-interaction>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:5145684"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:67a442d044446c216d98f4d5e5378c53"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:3ac8021b2642a9128c78c284c7028dbf"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA450350"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00351_4"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00286">
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:1a9eaebc7a9e13ecef618bd208176f9a"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_2"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00418"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4200"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6158"/>
    <ns4:mechanism-of-action>Estrogens enter the cells of responsive tissues (e.g., female organs, breasts, hypothalamus, pituitary) where they interact with a protein receptor, subsequently increasing the rate of synthesis of DNA, RNA, and some proteins. Estrogens decrease the secretion of gonadotropin-releasing hormone by the hypothalamus, reducing the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary.</ns4:mechanism-of-action>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:7bee213832292f1d1685c7e46f011925"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6142"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic/conest.htm"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00849"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_12"/>
    <ns4:protein-binding>90% bound to plasma proteins</ns4:protein-binding>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6155"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:b3d6bcfc1d738b78079c0c0adf194f7d"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:22c3575a33fa1ede0003984e74e9ebc0"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:bcdd8c2bc33cc44cdfede0d72251e00f"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6157"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:b2fd883578f6b7ca6f161a63df3fe01a"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4d23319cc446077177b9a89dcba1d840"/>
    <ns4:substructure>Steroids and Steroid Derivatives</ns4:substructure>
    <ns4:category>Estrogens</ns4:category>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:25712c4f118f9770658eda79e28989a3"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4486e5dbda253f0eb6cd0910b0cc2771"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4cda5795237f27a42765bba2e5a65196"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:G03CA57"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8d44276870e140a7b9bd40131dc9a54c"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:136"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00241_DB00286"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_8"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_3"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c0b36bcdbdbd6a3cba0bde8bf6364b8c"/>
    <ns4:substructure>Sulfate Esters</ns4:substructure>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:9472c69b34f85751a3f5a9c7c718dc00"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_16"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:e02ba2277e36838c89ab2131f4332e09"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6139"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00400"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:572844ece0a88c72b81f2c1c6bb50724"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:7f288dbcdb7cad2ae5480cc0239c7235"/>
    <ns4:substructure>Phenols and Derivatives</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c120a2e976eb7e50b5ca43b7be868c2e"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4f49c32361d1f0eb4e17f2bb11390fa4"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:9979efa02008d5aa88d2ad442fd431a3"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6160"/>
    <ns4:indication>For the treatment of moderate to severe vasomotor symptoms associated with the menopause, atrophic vaginitis, osteoporosis, hypoestrogenism due to hypogonadism, castration, primary ovarian failure, breast cancer (for palliation only), and Advanced androgen-dependent carcinoma of the prostate (for palliation only)</ns4:indication>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:78be668105544a8b0568e3522b6d4112"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_14"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:5547948"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_17"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:1c02d09e312c9e902a8f4dab816267aa"/>
    <ns4:route-of-elimination>Estradiol, estrone, and estriol are excreted in the urine, along with glucuronide and sulfate conjugates. Exogenous estrogens are metabolized in the same manner as endogenous estrogens.</ns4:route-of-elimination>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6141"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f110e28c1f70fae6b3d63b02a11ce75a"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:3f78f359ead2cb3f86303c2704b03cd1"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1732"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:bb6b2f332c9c4f014e10fb092ec58203"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:16f6c278df8a567c6d17115d4c1bdebe"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:53003f6e22cf8f3a538007e9692ba3a9"/>
    <ns4:biotransformation>Hepatic</ns4:biotransformation>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:000a3dc9413adbd6109d1da84aef32fd"/>
    <ns4:substructure>Sulfonyls</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_4"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:cf0085c2476cdba766a7385d23ed91f6"/>
    <ns4:synonym>Estrogens</ns4:synonym>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_7"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:487cbb24a3c54fb164f15a51ec74d338"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:42486dbcc63e4276076f467eb2c1342f"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4a6f822203ded2da95b26477d2902d88"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:a1b08d505e67d47ae51ccba8a9ba75e2"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/conjugated-estrogens.html"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1709"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00794"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6149"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f9c9f4aa6a0e99f6fb25ca7169c76b2f"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6166"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:862"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:64ec7a065e43780351382ca8ecd6d103"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:e920f0454d69c249bd6aedffbf508f7d"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_9"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00237_DB00286"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4df30095f944c9fe50fbeb7be7585c91"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:23667301"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:caa2f904b4b08155f8e4a58d9222f4a4"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c47af34a57aea45ad658a2361c00a973"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00532"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1588"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6167"/>
    <ns4:half-life>7.4 hours</ns4:half-life>
    <ns4:substructure>Anions</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:31fba980b20387c458a3b9eeedde77c7"/>
    <ns4:manufacturer>Wyeth pharmaceuticals inc</ns4:manufacturer>
    <ns4:substructure>Cyclohexenes and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_10"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1729"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:55e420d8dc56212be8b16f23a0e0a62b"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1490"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00312"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00286"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:2164"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00474"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:substructure>Carbonyl Compounds</ns4:substructure>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00286_1"/>
    <ns4:brand>Conestoral</ns4:brand>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB01355"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:fb2ed4a8c8baa97948d36b046d3c0c81"/>
    <ns4:substructure>Phenyl Esters</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2239655"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:5af7aeb2aaf72bc6938e3e6a18d049f9"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46505680"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4508ae37b41a8d06d1614f85e851b0e5"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8be1de9191eec2dec03cd80888b77ff5"/>
    <ns4:pharmacology>Conjugated estrogens, a mixture of the water soluble salts of sulfate esters from estrone, equilin, 17 &amp;alpha;-dihydroequilin, and other related steroids, may be derived from pregnant equine urine or yam and soy plants. Estrogens are important in the development and maintenance of the female reproductive system and secondary sex characteristics. They promote growth and development of the vagina, uterus, and fallopian tubes, and enlargement of the breasts. Indirectly, they contribute to the shaping of the skeleton, maintenance of tone and elasticity of urogenital structures, changes in the epiphyses of the long bones that allow for the pubertal growth spurt and its termination, growth of axillary and pubic hair, and pigmentation of the nipples and genitals. Decline of estrogenic activity at the end of the menstrual cycle can bring on menstruation, although the cessation of progesterone secretion is the most important factor in the mature ovulatory cycle. However, in the preovulatory or nonovulatory cycle, estrogen is the primary determinant in the onset of menstruation. Estrogens also affect the release of pituitary gonadotropins. The pharmacologic effects of conjugated estrogens are similar to those of endogenous estrogens.</ns4:pharmacology>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:5e44d0d8bad42e310fa3652b2634c856"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:5908638"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB01354"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:9a60859e6d4c752c7ce60d43f45b072a"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4ba1a4a56ff662677f1468a840661181"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:36458234eec4b8585da69e2db5230d14"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:14f62e8223b69c118c450dd0a863a905"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_13"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:638561acfa76d9947674dd9089bdffb7"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_11"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:14523e2498086b9f99333997452e7119"/>
    <ns4:category>Approved</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00252_DB00286"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00481"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:9532"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:c77230928873b45fc6c1ae779f31dbba"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8a7d4af18b64df6b29be9483344342ef"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00306"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:13e8d5e28fb251ec51bdad66d6544621"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:3810"/>
    <ns4:substructure>Naphthalenes</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00932"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:d162ec82e36d618ad6bafea8c777eea2"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00860"/>
    <ns4:substructure>Cations</ns4:substructure>
    <ns4:food-interaction>Avoid alcohol.</ns4:food-interaction>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00635"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6153"/>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <dcterms:description xml:lang="en">Conjugated estrogens, a mixture of the water-soluble salts of sulfate esters from estrone, equilin, 17 α-dihydroequilin, and other related steroids, may be derived from pregnant equine urine or yam and soy plants. Estrogens are important in the development and maintenance of the female reproductive system and secondary sex characteristics.</dcterms:description>
    <ns4:substructure>Sulfuric Acids and Derivatives</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c202260ac88bd5da38a35fe81fd86c7c"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:6d87505c1c65a887434d8a862ec3a4e9"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00754"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0046-0872-93"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00286"/>
    <ns4:toxicity>Nausea and vomiting</ns4:toxicity>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_6"/>
    <ns4:substructure>Ketones</ns4:substructure>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:absorption>Well absorbed</ns4:absorption>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:373444fdfe80be04c4adb1ebe72b460a"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB01174"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB01320"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:438-67-5"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_5"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1024"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:48f125d66776ef9d2feb4111bdcae396"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:de5d3bd460be252fe35f438d64ddadaf"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:34295c2ab97071008a0282d3db6f5983"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1632"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:68:16.04"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB01352"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB01353"/>
    <rdfs:label xml:lang="en">Conjugated Estrogens [drugbank:DB00286]</rdfs:label>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Prempro"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB01351"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:d0f70fb2747d3c6295241d4c6305a618"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_19"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:70b8c248ecde593c8beca691c2e8df2b"/>
    <ns4:substructure>Phenanthrenes</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:d38ee4b0150e41f1c9ef57355cbf0f95"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_18"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB01586"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:50f8018e03343e3ef9052188e1b6d7ac"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00286_15"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1735"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00285">
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_7"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:09fa36627661ee76666a8c49feafc48a"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:6cae29e5b3b7c310532deb2c220a4fa2"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4df30095f944c9fe50fbeb7be7585c91"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:dbcff6984cd9c1eebe840385c0d5a44c"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00668"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01105"/>
    <rdfs:label xml:lang="en">Venlafaxine [drugbank:DB00285]</rdfs:label>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:b8a4842c4418eea86b8abf1c30827996"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00951"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:713"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00619"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:a20666ab16acc4bc5c1887ca4a6be6e2"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01110"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01186"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00976"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:e78c64f9450eed30303fca369ba4a9a3"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Venlafaxine"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_13"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_9"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8a7d4af18b64df6b29be9483344342ef"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:fa1194a61cb470efd26d794228b8359d"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_15"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4757"/>
    <ns4:substructure>Phenyl Esters</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:27be2bce0e3d2258e38abaffcb1ac181"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01263"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01233"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c0b36bcdbdbd6a3cba0bde8bf6364b8c"/>
    <ns4:toxicity>Most patients overdosing with venlafaxine develop only mild symptoms. However, severe toxicity is reported with the most common symptoms being CNS depression, serotonin toxicity, seizure, or cardiac conduction abnormalities. Venlafaxine's toxicity appears to be higher than other SSRIs, with a fatal toxic dose closer to that of the tricyclic antidepressants than the SSRIs. Doses of 900 mg or more are likely to cause moderate toxicity. Deaths have been reported following large doses.</ns4:toxicity>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/venlafaxine.html"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01211"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00176_DB00285"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:5916923"/>
    <ns4:route-of-elimination>Renal elimination of venlafaxine and its metabolites is the primary route of excretion.</ns4:route-of-elimination>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB04896"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:de5d3bd460be252fe35f438d64ddadaf"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:4d8268d813a4db51a683253d5661fc73"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:d3d76d2df034b7906d0739954a57a04b"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01069"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00752"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:brand>Effexor</ns4:brand>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB06700"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00476"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:6a44b5a31bbce2db9bd294eb708dc41f"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00579"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01168"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:70b8c248ecde593c8beca691c2e8df2b"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01151"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00934"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:d7af4fd7699d8cdb0494a39d68797e2a"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00918"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:fa07ea4d90acd75ace99b0b42a346da1"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8b94de7669b3b2ef38c3f4637a78f8a8"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:a252f101d9bd96d0b03d39e9701146d0"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:48f125d66776ef9d2feb4111bdcae396"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00503"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:acfcf2804dd1b9542bf57489b4f38ae9"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00224_DB00285"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00193_DB00285"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00472"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4486e5dbda253f0eb6cd0910b0cc2771"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:a9d72ff8d93b080cadd433c57f979d37"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_18"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00285_2"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01191"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00477"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00248_DB00285"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:83e8964d34911b6e17b185639f8cedd5"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00582"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:f4285d3acd5a10f2197b421717e5f01b"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6030"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:b6f19395c878ed9ddebb1da80490173b"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:c75a7e879abc653c5cdb71544444a284"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00321"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01026"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:9ddbd94f4bf04baf4e7cfbd59e7d4a22"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:78be668105544a8b0568e3522b6d4112"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01323"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:42486dbcc63e4276076f467eb2c1342f"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:0d163419cd19cc76b1254df76b140f49"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:28:16.04.92"/>
    <ns4:substructure>Phenols and Derivatives</ns4:substructure>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:ae4758ea5a9ba6b4f9cf6810f18b6e44"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00353"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01367"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:7d05181629015df36258f000568f2ee0"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4d23319cc446077177b9a89dcba1d840"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00780"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:5454"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:fde0696c82762c238df74a19f75cd79f"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00857"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:8cbb445d5c91c56e13c01c2d35658cca"/>
    <ns4:category>Approved</ns4:category>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:6274171"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:f3f2d9887e28c6f01ed73c4d457f877e"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01167"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00449"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1588"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01171"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_6"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:adda4481003cc126448a0fcb432bebc5"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:86fd7c352e375e550611ea4ba86c4d40"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01182"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00514"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_10"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:N06AX16"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:93413-69-5"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f5a2c060dbdf170bf7617e432f4c60d9"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01601"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01104"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00908"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:f955424e91218a5d44fbc4acc78bac57"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:ffba89074d1ecdd2db570972a85919b1"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00220_DB00285"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_17"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00705"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:da42231f5ad3e6140dfa316b25f064c7"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:31eb30ebb28e24badd1fe8aa72840689"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:2e290cbb14a1bbf0007d0b0a00b7f896"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00726"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C07187"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00937"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8d6582bd6deabd0b41953de93b5e29c0"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:dac321348f83b324b5d3db4ca329bbf8"/>
    <ns4:substructure>Cumenes and Derivatives</ns4:substructure>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:6649f11da4cb2ff6348fea324ce4cd40"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00574"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2199778"/>
    <ns4:mechanism-of-action>The exact mechanism of action of venlafaxine is unknown, but appears to be associated with the its potentiation of neurotrasmitter activity in the CNS. Venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), inhibit the reuptake of both serotonin and norepinephrine with a potency greater for the 5-HT than for the NE reuptake process. Both venlafaxine and the ODV metabolite have weak inhibitory effects on the reuptake of dopamine but, unlike the tricyclics and similar to SSRIs, they are not active at histaminergic, muscarinic, or alpha(1)-adrenergic receptors.</ns4:mechanism-of-action>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00601"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4508ae37b41a8d06d1614f85e851b0e5"/>
    <ns4:substructure>Alcohols and Polyols</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01364"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01142"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4d1948e403f641887747ddfdd191e9dd"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01072"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00953"/>
    <dcterms:description xml:lang="en">Venlafaxine (Effexor) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class first introduced by Wyeth in 1993. It is prescribed for the treatment of clinical depression and anxiety disorders. Due to the pronounced side effects and suspicions that venlafaxine may significantly increase the risk of suicide it is not recommended as a first line treatment of depression. However, it is often effective for depression not responding to SSRIs. Venlafaxine was the sixth most widely-used antidepressant based on the amount of retail prescriptions in the US (17.1 million) in 2006. [Wikipedia]</dcterms:description>
    <ns4:category>Antidepressants</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00191_DB00285"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c120a2e976eb7e50b5ca43b7be868c2e"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:7d0b4fcc6c118d291574e0e351e57389"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00701"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:c0d49e3cafa4ce310b87b14be6033b31"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:191f70e2703ea0892c8e15215df95d5e"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00285_1"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2126305"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:b48d890a81955f264a33a85db3b06c69"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01200"/>
    <ns4:substructure>Phenethylamines</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2237279"/>
    <ns4:biotransformation>Undergoes extensive first pass metabolism in the liver to its major, active metabolite, ODV, and two minor, less active metabolites, N-desmethylvenlafaxine and N,O-didesmethylvenlafaxine. Formation of ODV is catalyzed by cytochrome P450 (CYP) 2D6, whereas N-demethylation is catalyzed by CYP3A4, 2C19 and 2C9. ODV possesses antidepressant activity that is comparable to that of venlfaxine. </ns4:biotransformation>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:81dbf0698deb1cd002cde7812ac0e58e"/>
    <ns4:protein-binding>venlafaxine, 27%; ODV, 30%</ns4:protein-binding>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00454"/>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00622"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00427"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01369"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:dcee7f3281e82b86b964c5b6901d34b3"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_19"/>
    <ns4:indication>For the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, and vasomotor symptoms in women with breast cancer and in postmenopausal women.</ns4:indication>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01012"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:bcdd8c2bc33cc44cdfede0d72251e00f"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00907"/>
    <rdfs:seeAlso rdf:resource="http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=eff1794.html&amp;contentName=Effexor%20XR&amp;contentId=277"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8be1de9191eec2dec03cd80888b77ff5"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:128979382d400192486a16d81fa406f0"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:34295c2ab97071008a0282d3db6f5983"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01149"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:dd346a4d24f96a3f5a42b5112e667306"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:bb5ed3b56e869ff50155648ccdc09020"/>
    <ns4:food-interaction>Avoid alcohol.</ns4:food-interaction>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_8"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:373444fdfe80be04c4adb1ebe72b460a"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:6de56ced2b8c3a424a2c215be6e2687f"/>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:9943"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:50f8018e03343e3ef9052188e1b6d7ac"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01356"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00852"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00216_DB00285"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00614"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00669"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:ad26ea1134e4e9136f87a6d1aa796e06"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01175"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_16"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00315"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01049"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:ce0032c50f621fb65b54ff4e30a93a41"/>
    <ns4:half-life>5 hours</ns4:half-life>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4119"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00998"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00320"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f754e930893361a7f5ebccdd968d152a"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_14"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0378-4881-01"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00872"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:9ad0d922e88513f4f547a7e4b6e66120"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01264"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:360749e001c13a07393629f8617ee477"/>
    <ns4:manufacturer>Wyeth pharmaceuticals inc</ns4:manufacturer>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_3"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:d7a41e61ee7d79b553d55baf4f2be8f6"/>
    <ns4:substructure>Aliphatic and Aryl Amines</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01247"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00656"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:dd6af06f38d938851b3cb658468f6422"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:7bee213832292f1d1685c7e46f011925"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:ff328bd557dd45b4dc0d787972ae2c2a"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_5"/>
    <ns4:synonym>Venlafaxina [INN-Spanish]</ns4:synonym>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:2445487b59b28c06af3c629ca90fa76a"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00368"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_12"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00458"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_4"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01232"/>
    <ns4:pharmacology>Venlafaxine, an antidepressant agent structurally and pharmacologically unrelated to other antidepressants and agents used to treat generalized anxiety disorder, is used to treat melancholia, generalized anxiety disorder (GAD), panic disorder, post-traumatic stress disorder, and hot flashes in breast cancer survivors.</ns4:pharmacology>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00285"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01319"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01037"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:bb6b2f332c9c4f014e10fb092ec58203"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:824"/>
    <ns4:volume-of-distribution>* 7.5 ± 3.7 L/kg [venlafaxine]
* 5.7 ± 1.8 L/kg [O-desmethylvenlafaxine(active metabolite)]</ns4:volume-of-distribution>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:64ec7a065e43780351382ca8ecd6d103"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:7e99932db28b877cb59b18bf5637cf5a"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00397"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00285_11"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00490"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00715"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6016"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00540"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:540"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA451866"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:8b665467e017d845799aed30fead4739"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:caa2f904b4b08155f8e4a58d9222f4a4"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:3eca9b571a65ee54521776e1c00cf44f"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01253"/>
    <ns4:absorption>Bioavailability is 45% following oral administration.</ns4:absorption>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00344"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00696"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic/venlafax.htm"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:5656"/>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00952"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:9f3102cfa23b5d21807fc1f97a8f93cb"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00543"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:substructure>Anisoles</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46504593"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00285"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB01242"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00118_DB00285"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00285_DB00370"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:bf77a7ebe7405467f5b98fa7d8f47c1b"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00215_DB00285"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB03010">
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2601"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_3"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_4"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_15"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2539"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2444"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2565"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_8"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_5"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2578"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46505629"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_12"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pdb:EPB"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB03010"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_7"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_6"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:152044-54-7"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_17"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:46936553"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_1"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_10"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_13"/>
    <ns4:mechanism-of-action>The principal mechanism of the epothilone class is inhibition of microtubule function. Microtubules are essential to cell division, and epothilones therefore stop cells from properly dividing. Epothilone B possess the same biological effects as taxol both in vitro and in cultured cells. This is because they share the same binding site, as well as binding affinity to the microtubule. Like taxol, epothilone B binds to the αβ-tubulin heterodimer subunit. Once bound, the rate of αβ-tubulin dissociation decreases, thus stabilizing the microtubules. Furthermore, epothilone B has also been shown to induce tubulin polymerization into microtubules without the presence of GTP. This is caused by formation of microtubule bundles throughout the cytoplasm. Finally, epothilone B also causes cell cycle arrest at the G2-M transition phase, thus leading to cytotoxicity and eventually cell apoptosis.</ns4:mechanism-of-action>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_18"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2480"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_16"/>
    <ns4:synonym>EPO 906</ns4:synonym>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_11"/>
    <rdfs:label xml:lang="en">Epothilone B [drugbank:DB03010]</rdfs:label>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_14"/>
    <ns4:indication>Investigated for use/treatment in ovarian cancer, lung cancer, brain cancer, breast cancer, and gastric cancer.</ns4:indication>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:category>Small molecule</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_2"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2449"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2342"/>
    <ns4:category>Experimental</ns4:category>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:161"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB03010_9"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <dcterms:description xml:lang="en">Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.</dcterms:description>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB03010"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2499"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:29"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2536"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB01248">
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01026_DB01248"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00624_DB01248"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01248_DB01321"/>
    <ns4:substructure>Benzoyl Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00199_DB01248"/>
    <ns4:protein-binding>About 94% protein bound, mainly to a1-acid glycoprotein, albumin, and lipoproteins.</ns4:protein-binding>
    <ns4:substructure>Alcohols and Polyols</ns4:substructure>
    <ns4:substructure>Benzoates</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_18"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:4814470"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_5"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Docetaxel"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_9"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:5eb0e48397e49e2e9e53a1bd4243c4f1"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00976_DB01248"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic3/docetaxel.htm"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_16"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:substructure>Acetates</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:114977-28-5"/>
    <ns4:manufacturer>Sanofi aventis us llc</ns4:manufacturer>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2149055"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00582_DB01248"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46506766"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00385_DB01248"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:29"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00958_DB01248"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2150576"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6107"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C11231"/>
    <ns4:category>Approved</ns4:category>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB01248"/>
    <ns4:substructure>Cyclooctane and Derivatives</ns4:substructure>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/docetaxel.html"/>
    <rdfs:label xml:lang="en">Docetaxel [drugbank:DB01248]</rdfs:label>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L01CD02"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1588"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01248_DB01369"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_12"/>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_8"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:1898"/>
    <ns4:substructure>Glycerol and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_3"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01248_DB01420"/>
    <ns4:volume-of-distribution>* 113 L</ns4:volume-of-distribution>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_20"/>
    <ns4:brand>Taxotere</ns4:brand>
    <ns4:substructure>Taxanes</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:4672"/>
    <ns4:substructure>Alkanes and Alkenes</ns4:substructure>
    <ns4:pharmacology>Docetaxel is a taxoid antineoplastic agent. It promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, docetaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.</ns4:pharmacology>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:eb9827ee82300f9e35cdc29eab329fe8"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA449383"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00515_DB01248"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_15"/>
    <ns4:substructure>Benzyl Alcohols and Derivatives</ns4:substructure>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01248"/>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:5438072"/>
    <ns4:half-life>Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. Alpha (distribution) 4 minutes. Beta 36 minutes. Gamma (terminal) 11.1 hours.</ns4:half-life>
    <ns4:substructure>Ketones</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_10"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4118"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB01248"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_14"/>
    <ns4:route-of-elimination>Docetaxel was eliminated in both the urine and feces following oxidative metabolism of the tert-butyl ester group, but fecal excretion was the main elimination route. Within 7 days, urinary and fecal excretion accounted for approximately 6% and 75% of the administered radioactivity, respectively.</ns4:route-of-elimination>
    <ns4:synonym>Docetaxel anhydrous</ns4:synonym>
    <ns4:toxicity>Oral LD&lt;sub&gt;50&lt;/sub&gt; in rat is &gt;2000 mg/kg. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. In two reports of overdose, one patient received 150 mg/m&lt;sup&gt;2&lt;/sup&gt; and the other received 200 mg/m&lt;sup&gt;2&lt;/sup&gt; as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.</ns4:toxicity>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_11"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_7"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB01248_2"/>
    <ns4:indication>For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Lastly, for use, in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.</ns4:indication>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:273"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2177080"/>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:substructure>Cyclohexenes and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_17"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:4b5c0bb3f1d90576a038a3f972025295"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_19"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:148124"/>
    <ns4:mechanism-of-action>Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the &amp;beta;-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.</ns4:mechanism-of-action>
    <ns4:biotransformation>Hepatic. In vitro drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme (1 major, 3 minor metabolites).</ns4:biotransformation>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_13"/>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_6"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:130581"/>
    <dcterms:description xml:lang="en">Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of 1 mole docetaxel per mole tubulin in microtubules.</dcterms:description>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:substructure>Short-chain Hydroxy Acids</ns4:substructure>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00673_DB01248"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00683_DB01248"/>
    <ns4:substructure>Cyclobutane and Derivatives</ns4:substructure>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB01248_1"/>
    <ns4:substructure>Carboxylic Acids and Derivatives</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01173_DB01248"/>
    <ns4:substructure>Carbonyl Compounds</ns4:substructure>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:substructure>Carbamates and Derivatives</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0075-8001-80"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01248_4"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6148"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB01006">
    <ns4:substructure>Cyanides</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8be1de9191eec2dec03cd80888b77ff5"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_3"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:absorption>Rapidly and completely absorbed. Absorption is not affected by food.</ns4:absorption>
    <ns4:substructure>Nitriles and Derivatives</ns4:substructure>
    <rdfs:label xml:lang="en">Letrozole [drugbank:DB01006]</rdfs:label>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L02BG04"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_17"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:3765"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:112809-51-5"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_16"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D00964"/>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_5"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:4978672"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:2d084da4f390415483791184057229f4"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:6413"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_7"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C08163"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_2"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic2/letroz.htm"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:3811"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB01006"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_12"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_15"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:3902"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_10"/>
    <ns4:food-interaction>Take without regard to meals. Food slows absorption without decreasing the quantity absorbed.</ns4:food-interaction>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:5718"/>
    <ns4:manufacturer>Novartis pharmaceuticals corp</ns4:manufacturer>
    <ns4:category>Approved</ns4:category>
    <dcterms:description xml:lang="en">Letrozole (INN, trade name Femara®) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast cancer

Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Letrozole blocks production of estrogens in this way by competitive, reversible binding to the heme of its cytochrome P450 unit. The action is specific, and letrozole does not reduce production of mineralo- or corticosteroids. In contrast, the antiestrogenic action of tamoxifen, the major medical therapy prior to the arrival of aromatase inhibitors, is due to its interfering with the estrogen receptor, rather than inhibiting estrogen production.
Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. Side effects include signs and symptoms of hypoestrogenism. There is concern that long term use may lead to osteoporosis, which is why prescriptions of Letrozole are often accompanied by prescriptions of osteoporosis-fighting medication such as Fosamax.
Letrozole has shown to reduce estrogen levels by 98 percent while raising testosterone levels. The anti-estrogen action of letrozole is preferred by athletes and bodybuilders for use during a steroid cycle to reduce bloating due to excess water retention and prevent the formation of gynecomastia related breast tissue that is a side effect of some anabolic steroids. Usage above 2.5 mg/day is known to potentially temporarily kill sex drive. Above 5mg/day for extended periods may cause kidney problems.

Letrozole has also been shown to delay the fusing of the growth plates in adolescents. This may boost the effectiveness of growth hormone, and thus Letrozole is used to treat adolescents and children with short stature.</dcterms:description>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_18"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:half-life>2 days</ns4:half-life>
    <ns4:substructure>Cyanamides</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2231384"/>
    <ns4:brand>Femara</ns4:brand>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_8"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/letrozole.html"/>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:substructure>Diphenylmethanes</ns4:substructure>
    <ns4:pharmacology>Letrozole is an aromatase inhibitor used in the treatment of breast cancer. Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization. As breast tissue is stimulated by estrogens, decreasing their production is a way of suppressing recurrence of the breast tumor tissue.</ns4:pharmacology>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA450196"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_13"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_6"/>
    <ns4:mechanism-of-action>Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. In adult nontumor- and tumorbearing female animals, letrozole is as effective as ovariectomy in reducing uterine weight, elevating serum Leuteinizing hormone (LH), and causing the regression of estrogen-dependent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum (folicile stimulating hormone (FSH). Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis.</ns4:mechanism-of-action>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Letrozole"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_11"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB01006_1"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3811"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_14"/>
    <ns4:substructure>Triazoles</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/bindingdb:13061"/>
    <ns4:synonym>Letrozol</ns4:synonym>
    <ns4:indication>For the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. Also for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.</ns4:indication>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:54252257586a6492da9610249ec2bd4b"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_4"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46504610"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB01006"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01006_9"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:caa2f904b4b08155f8e4a58d9222f4a4"/>
    <ns4:biotransformation>Primarily hepatic via CYP3A4 and CYP2A6. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. It is metabolized slowly to an inactive metabolite whose glucuronide conjugate is excreted renally, representing the major clearance pathway.</ns4:biotransformation>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB06287">
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01174_DB06287"/>
    <ns4:protein-binding>87% bound to plasma proteins &lt;i&gt;in vitro&lt;/i&gt; at a concentration of 100 ng/ml</ns4:protein-binding>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01263_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00357_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00794_DB06287"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB06287"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:42486dbcc63e4276076f467eb2c1342f"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6107"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00312_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00607_DB06287"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00564_DB06287"/>
    <ns4:synonym>CCI-779</ns4:synonym>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00951_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01320_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00503_DB06287"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2429020"/>
    <ns4:substructure>Carboxylic Acids and Derivatives</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L01XE09"/>
    <ns4:substructure>Acetates</ns4:substructure>
    <ns4:indication>For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.</ns4:indication>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:ab545f97675ee7a7fe844f2598c0b887"/>
    <ns4:substructure>Lactams</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01072_DB06287"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:99443243"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:5362718"/>
    <ns4:volume-of-distribution>172 L in whole blood of cancer patients; both temsirolimus and sirolimus are extensive distributed partitioned into formed blood elements</ns4:volume-of-distribution>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00108_DB06287"/>
    <ns4:substructure>Amino Acids</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01045_DB06287"/>
    <ns4:substructure>Pyrans</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00701_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01167_DB06287"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic/torisel.htm"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C15182"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00932_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01601_DB06287"/>
    <ns4:substructure>Carbonyl Compounds</ns4:substructure>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/temsirolimus.html"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:half-life>Temsirolimus exhibits a bi-exponential decline in whole blood concentrations and the mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.</ns4:half-life>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_4"/>
    <ns4:absorption>Infused intravenous over 30 - 60 minutes. C&lt;sub&gt;max&lt;/sub&gt; is typically observed at the end of infusion</ns4:absorption>
    <rdfs:label xml:lang="en">Temsirolimus [drugbank:DB06287]</rdfs:label>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2187024"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00615_DB06287"/>
    <ns4:substructure>Lactones</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01211_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01323_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00625_DB06287"/>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01319_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00224_DB06287"/>
    <ns4:substructure>Piperidines</ns4:substructure>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4118"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_2"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_18"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_17"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:4148"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01232_DB06287"/>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00441_DB06287"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00622_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00976_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01110_DB06287"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:ba3f5c0cb932b493cb1efb38836b76cc"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00544_DB06287"/>
    <ns4:substructure>Aliphatic and Aryl Amines</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00519_DB06287"/>
    <ns4:brand>Torisel</ns4:brand>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01264_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00559_DB06287"/>
    <ns4:substructure>Carboxamides and Derivatives</ns4:substructure>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Temsirolimus"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01026_DB06287"/>
    <ns4:substructure>Ketones</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_16"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00776_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00908_DB06287"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_3"/>
    <ns4:substructure>Acetals and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_5"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_9"/>
    <ns4:substructure>Alcohols and Polyols</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01234_DB06287"/>
    <ns4:substructure>Amino Ketones</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00220_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01268_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01149_DB06287"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_6"/>
    <dcterms:description xml:lang="en">Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative of sirolimus and is sold as Torisel.</dcterms:description>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_1"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_12"/>
    <ns4:manufacturer>Wyeth pharmaceuticals inc</ns4:manufacturer>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:12b602d1a58cee5fd367ef9e50edaa3f"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00619_DB06287"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_15"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00252_DB06287"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB06287"/>
    <ns4:route-of-elimination>Excreted predominantly in feces (76%), 4.6% of drug and metabolites recovered in urine. 17% of drug was not recovered by either route following a 14-day sample collection. </ns4:route-of-elimination>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_11"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_13"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4119"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:4b5c0bb3f1d90576a038a3f972025295"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_8"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01201_DB06287"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:162635-04-3"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_14"/>
    <ns4:category>Approved</ns4:category>
    <ns4:toxicity>Temsirolimus has been administered to patients with cancer in phase 1 and 2 trials with repeated intravenous doses as high as 220 mg/m2. The risk of several serious adverse events, including thrombosis, bowel perforation, interstitial lung disease (ILD), seizure, and psychosis, is increased with doses of temsirolimus greater than 25 mg.</ns4:toxicity>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00238_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00864_DB06287"/>
    <ns4:substructure>Alkanes and Alkenes</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00872_DB06287"/>
    <ns4:mechanism-of-action>Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.</ns4:mechanism-of-action>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00582_DB06287"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00705_DB06287"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:23724530"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_7"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:21468899"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:b9db2fe4cd4014a788856441f9d848b8"/>
    <ns4:biotransformation>Primarily metabolized by cytochrome P450 3A4 in the human liver. Sirolimus, an equally potent metabolite, is the primary metabolite in humans following IV infusion. Other metabolic pathways observed in &lt;i&gt;in vitro&lt;/i&gt; temsirolimus metabolism studies include hydroxylation, reduction and demethylation. </ns4:biotransformation>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1588"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06287_10"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D06068"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB01042">
    <ns4:half-life>1.5 (&amp;plusmn;0.83) hours</ns4:half-life>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB01042"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_10"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_8"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_11"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8be1de9191eec2dec03cd80888b77ff5"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:148-82-3"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_14"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB01042_2"/>
    <ns4:food-interaction>Take on an empty stomach. Food decreases bioavailabilty by approximately 30%. Increase liquid intake.</ns4:food-interaction>
    <ns4:xref rdf:resource="http://bio2rdf.org/bindingdb:50038356"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:874"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00091_DB01042"/>
    <ns4:protein-binding>Moderate to high (60 to 90%), primarily to albumin and, to a lesser extent, alpha 1-acid glycoprotein. 30% is irreversibly bound.</ns4:protein-binding>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0173-0045-35"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:18ff47f84d5428f7ac02e7d0e70ac2a9"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_9"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:28876"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:category>Antineoplastic Agents, Alkylating</ns4:category>
    <ns4:indication>For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.</ns4:indication>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_3"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/melphalan.html"/>
    <ns4:brand>Alkeran</ns4:brand>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_13"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:d8ba9d7456858777c306fd8433eeca10"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_18"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_12"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB01042_1"/>
    <ns4:biotransformation>Melphalan is not actively metabolised, it spontaneously degrades to mono and dihydroxy products.</ns4:biotransformation>
    <rdfs:label xml:lang="en">Melphalan [drugbank:DB01042]</rdfs:label>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic2/melph.htm"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB01042"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_7"/>
    <ns4:absorption>Incomplete, variable, 25-89% post oral dose</ns4:absorption>
    <ns4:category>Approved</ns4:category>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:196e19ca6d87df6b5e201da96924cead"/>
    <ns4:manufacturer>Glaxosmithkline</ns4:manufacturer>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_4"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L01AA03"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:abcf0f981387f9e56f1d9ddcc8fd67cd"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:c412e741942d6195f0685690fabd6131"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA450354"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_17"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_19"/>
    <ns4:route-of-elimination>The 24-hour urinary excretion of parent drug in these patients was 10% ± 4.5%, suggesting that renal clearance is not a major route of elimination of parent drug.</ns4:route-of-elimination>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:1341114"/>
    <ns4:toxicity>Vomiting, ulceration of the mouth, diarrhea, and hemorrhage of the gastrointestinal tract; The principal toxic effect is bone marrow suppression. LD&lt;sub&gt;50&lt;/sub&gt;=11.2 mg/kg (orally in rat)</ns4:toxicity>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:22c3575a33fa1ede0003984e74e9ebc0"/>
    <ns4:pharmacology>Melphalan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.</ns4:pharmacology>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_15"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:6147"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00072_DB01042"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_6"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8a7d4af18b64df6b29be9483344342ef"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Melphalan"/>
    <dcterms:description xml:lang="en">An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen. [PubChem]</dcterms:description>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D00369"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:615b8348f98e255ff2bb813aae7740d2"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:ab7562fe44f0cd2c7af6752104ff8c00"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_16"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f280408b4ef0dc77d3f8b34933605932"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:a3e4f2e247b932d877f0d3099dd5d372"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:4715"/>
    <ns4:mechanism-of-action>Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases (primarily at the N-7 position of guanine and to a lesser extent, at the N-3 position of adenine), forming monoadducts and resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.</ns4:mechanism-of-action>
    <ns4:volume-of-distribution>* 0.5 L/kg</ns4:volume-of-distribution>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:19bcb6c73e1414cc4ab588948e9c515e"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01042_5"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB04845">
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_2"/>
    <ns4:substructure>Epoxides</ns4:substructure>
    <ns4:route-of-elimination>Mostly fecal and some renal.</ns4:route-of-elimination>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_6"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_18"/>
    <rdfs:label xml:lang="en">Ixabepilone [drugbank:DB04845]</rdfs:label>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D04645"/>
    <ns4:indication>Investigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified).</ns4:indication>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:219989-84-1"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_17"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:4949236"/>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2578"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_13"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_9"/>
    <ns4:half-life>52 hours</ns4:half-life>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_3"/>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:category>Small molecule</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_8"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_11"/>
    <dcterms:description xml:lang="en">Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. [Wikipedia] Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that
minimizes susceptibility to esterase degradation.</dcterms:description>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:substructure>Thiazoles</ns4:substructure>
    <ns4:manufacturer>Bristol myers squibb co</ns4:manufacturer>
    <ns4:brand>Ixempra</ns4:brand>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_15"/>
    <ns4:category>Approved</ns4:category>
    <ns4:substructure>Imines</ns4:substructure>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB04845"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_16"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Ixabepilone"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00872_DB04845"/>
    <ns4:substructure>Lactams</ns4:substructure>
    <ns4:substructure>Alkanes and Alkenes</ns4:substructure>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L01DC04"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_7"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:99443224"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_1"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:23305354"/>
    <ns4:substructure>Carboxylic Acids and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_4"/>
    <ns4:substructure>Carboxamides and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_14"/>
    <ns4:substructure>Ketones</ns4:substructure>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:7312237"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00582_DB04845"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:6605599"/>
    <ns4:mechanism-of-action>Binding of Ixabepilone to beta-tubulins (e.g. beta-III tubulin) stabilizes microtubules. Microtubules are essential to cell division, and epothilones therefore stop cells from properly dividing. Like taxol, Ixabepilone binds to the αβ-tubulin heterodimer subunit. Once bound, the rate of αβ-tubulin dissociation decreases, thus stabilizing the microtubules.</ns4:mechanism-of-action>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB04845"/>
    <ns4:protein-binding>67-77%</ns4:protein-binding>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_5"/>
    <ns4:substructure>Amino Ketones</ns4:substructure>
    <ns4:synonym>Aza-epothilone B</ns4:synonym>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_10"/>
    <ns4:substructure>Carbonyl Compounds</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB04845_12"/>
    <ns4:substructure>Alcohols and Polyols</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00976_DB04845"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00112">
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3818"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:183"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:4b5c0bb3f1d90576a038a3f972025295"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic3/avastin.htm"/>
    <ns4:synonym>AntiVEGF</ns4:synonym>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:1102"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00112"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00112_DB01268"/>
    <ns4:brand>Avastin</ns4:brand>
    <ns4:biotransformation>Most likely removed by opsonization via the reticuloendothelial system when bound to endothelial cells, or by human antimurine antibody production</ns4:biotransformation>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:32c3298d35912d4688d23c5eb64805d1"/>
    <ns4:mechanism-of-action>Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. This prevents blood vessel proliferation and tumour metastasis.</ns4:mechanism-of-action>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/bevacizumab-solution.html"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3814"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00112"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3820"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:216974-75-3"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2270994"/>
    <ns4:pharmacology>Bevacizumab prevents or reduces the formation of blood vessels (angiogenesis) thereby preventing or reducing metatstatic disease progressing. Bevacizumab binds VEGF and prevents vascular endothelial growth and endothelial cell proliferation.</ns4:pharmacology>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L01XC07"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2286330"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3816"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3819"/>
    <ns4:category>Biotech</ns4:category>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3817"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:44f69c2f2cafbb8f91195a7c66dea66b"/>
    <dcterms:description xml:lang="en">A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.</dcterms:description>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2145985"/>
    <rdfs:label xml:lang="en">Bevacizumab [drugbank:DB00112]</rdfs:label>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:50242-060-01"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:784"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3821"/>
    <ns4:manufacturer>Roche Pharmaceuticals</ns4:manufacturer>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:97ec1d8cd1e1a741b51a1151859ee3e7"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3815"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:5f4df6d410318c0872a704ea3ca60a82"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Bevacizumab"/>
    <ns4:indication>As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.</ns4:indication>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA13023299"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:e7c136f8ca90ace8343567c266d8218e"/>
    <ns4:category>Approved</ns4:category>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00947">
    <dcterms:description xml:lang="en">Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.</dcterms:description>
    <ns4:toxicity>There is no clinical experience with overdosage in humans.</ns4:toxicity>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_15"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_18"/>
    <ns4:biotransformation>Metabolism of fulvestrant appears to involve combinations of a number of possible biotransformation pathways analogous to those of endogenous steroids, including oxidation, aromatic hydroxylation, conjugation with glucuronic acid and/or sulphate at the 2, 3 and 17 positions of the steroid nucleus, and oxidation of the side chain sulphoxide. Identified metabolites are either less active or exhibit similar activity to fulvestrant in antiestrogen models. Studies using human liver preparations and recombinant human enzymes indicate that cytochrome P-450 3A4 (CYP 3A4) is the only P-450 isoenzyme involved in the oxidation of fulvestrant; however, the relative contribution of P-450 and non-P-450 routes in vivo is unknown.</ns4:biotransformation>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:c7b9eb2d0a9f534fb102dbe975a18056"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/fulvestrant.html"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/gtp:1015"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_14"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_11"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_5"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/iuphar:1015"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic/faslodex.htm"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_9"/>
    <ns4:category>Approved</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_7"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA10086"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_19"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00947"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:129453-61-8"/>
    <ns4:route-of-elimination>Fulvestrant was rapidly cleared by the hepatobiliary route with excretion primarily via the feces (approximately 90%).
Renal elimination was negligible (less than 1%).</ns4:route-of-elimination>
    <ns4:synonym>ICI 182,780</ns4:synonym>
    <ns4:pharmacology>Fulvestrant for intramuscular administration is an estrogen receptor antagonist without known agonist effects.</ns4:pharmacology>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_13"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_16"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Fulvestrant"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/bindingdb:50169743"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:mechanism-of-action>Fulvestrant competitively and reversibly binds to estrogen receptors present in cancer cells and achieves its anti-estrogen effects through two separate mechanisms. First, fulvestrant binds to the receptors and downregulates them so that estrogen is no longer able to bind to these receptors. Second, fulvestrant degrades the estrogen receptors to which it is bound. Both of these mechanisms inhibit the growth of tamoxifen-resistant as well as estrogen-sensitive human breast cancer cell lines.</ns4:mechanism-of-action>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:volume-of-distribution>* 3 to 5 L/kg</ns4:volume-of-distribution>
    <ns4:indication>For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.</ns4:indication>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_6"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:6774122"/>
    <rdfs:label xml:lang="en">Fulvestrant [drugbank:DB00947]</rdfs:label>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:136"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L02BA03"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2248624"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2351004"/>
    <ns4:manufacturer>Astrazeneca pharmaceuticals lp</ns4:manufacturer>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_3"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_10"/>
    <ns4:protein-binding>99% (mainly VLDL, LDL, and HDL)</ns4:protein-binding>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D01161"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_17"/>
    <ns4:brand>Faslodex</ns4:brand>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8203e6d19514e57d2398d84da2a8d96f"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:2c3732d16bc150655742078a4f01df1c"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_2"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00947_1"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00947"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_12"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0310-0720-50"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:31638"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_8"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:a6238a751c87d8b2be124acbfb04118d"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00947_4"/>
    <ns4:half-life>40 days</ns4:half-life>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB01217">
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:78e4572c7cb80baf9d6c1bd044b25e6b"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:caa2f904b4b08155f8e4a58d9222f4a4"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:half-life>50 hours</ns4:half-life>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_5"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB01217_1"/>
    <ns4:substructure>Cyanamides</ns4:substructure>
    <ns4:substructure>Nitriles and Derivatives</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8be1de9191eec2dec03cd80888b77ff5"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_19"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:1ae36337444644aa75b8194e158047fb"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_12"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2224135"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4757"/>
    <rdfs:seeAlso rdf:resource="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ari1028.shtml"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4d2d18ad20fe49f6ffbc6e9796997266"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4d23319cc446077177b9a89dcba1d840"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:3811"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:10:00.00"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8b94de7669b3b2ef38c3f4637a78f8a8"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:mechanism-of-action>Anastrozole selectively inhibits aromatase. The principal source of circulating estrogen (primarily estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues. Therefore, aromatase inhibition leads to a decrease in serum and tumor concentration of estrogen, leading to a decreased tumor mass or delayed progression of tumor growth in some women. Anastrozole has no detectable effect on synthesis of adrenal corticosteroids, aldosterone, and thyroid hormone.</ns4:mechanism-of-action>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:fa1194a61cb470efd26d794228b8359d"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_18"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:ebbe785d5fdcc6d09b87401582c9959b"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:8fff60d9770cff01bde17d62da2a25c8"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c0b36bcdbdbd6a3cba0bde8bf6364b8c"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:1337420"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_11"/>
    <ns4:pharmacology>Anastrozole is a potent and selective non-steroidal aromatase inhibitor indicated for the treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy. Many breast cancers have estrogen receptors and growth of these tumors can be stimulated by estrogens. In post-menopausal women, the principal source of circulating estrogen (primarily estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues, such as adipose tissue, with further conversion of estrone to estradiol. Many breast cancers also contain aromatase; the importance of tumor-generated estrogens is uncertain. Treatment of breast cancer has included efforts to decrease estrogen levels by ovariectomy premenopausally and by use of anti-estrogens and progestational agents both pre- and post-menopausally, and these interventions lead to decreased tumor mass or delayed progression of tumor growth in some women. Anastrozole is a potent and selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.</ns4:pharmacology>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_16"/>
    <dcterms:description xml:lang="en">Anastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens.</dcterms:description>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_4"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Anastrozole"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C08159"/>
    <ns4:protein-binding>40%</ns4:protein-binding>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:dcee7f3281e82b86b964c5b6901d34b3"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB01217_2"/>
    <ns4:manufacturer>Accord healthcare inc usa</ns4:manufacturer>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_13"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:120511-73-1"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_7"/>
    <ns4:food-interaction>Food decreases the rate of absorption, but the extent of absorption is not affected.</ns4:food-interaction>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:f5a2c060dbdf170bf7617e432f4c60d9"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_17"/>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/bindingdb:10015"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:6ff839af31fdcb8875faa77203d367ae"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic2/anastr.htm"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:b086be3f9ca0e0ae5dbf28b1b8ba4215"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB01217"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:adda4481003cc126448a0fcb432bebc5"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4200"/>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_8"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:cdd5d654f44c5ef8cd81e586a82402a3"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:5ab3a3b5174abd2947f30ff88d5efc3d"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46504987"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8203e6d19514e57d2398d84da2a8d96f"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB01217"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:2187"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:73e8351efc5190a939c5f71c5a949ac1"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:2102"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_10"/>
    <ns4:indication>For adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in post-menopausal women. Has also been used to treat pubertal gynecomastia and McCune-Albright syndrome; however, manufacturer states that efficacy for these indications have not been established.</ns4:indication>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4c59c55b40056cbedf8473330a1c917f"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_14"/>
    <rdfs:label xml:lang="en">Anastrozole [drugbank:DB01217]</rdfs:label>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/anastrozole.html"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D00960"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA448432"/>
    <ns4:substructure>Triazoles</ns4:substructure>
    <ns4:category>Approved</ns4:category>
    <ns4:category>Small molecule</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_15"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:biotransformation>Hepatic. Metabolized mainly by N-dealkylation, hydroxylation, and glucuronidation to inactive metabolites. Primary metabolite is an inactive triazole.</ns4:biotransformation>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:3811"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_3"/>
    <ns4:synonym>Anastrozol</ns4:synonym>
    <ns4:brand>Anastrole</ns4:brand>
    <ns4:route-of-elimination>Hepatic metabolism accounts for approximately 85% of anastrozole elimination. Renal elimination accounts for approximately 10% of total clearance.</ns4:route-of-elimination>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:2704"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0310-0201-30"/>
    <ns4:absorption>Rapidly absorbed into the systemic cirulation following oral administration. Peak plasma concentrations are usually attained within 2 hours under fasting conditions, with steady-state plasma concentrations attained in approximately 7 days.</ns4:absorption>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:22925d6a0326ffd259ebe76b5f3b96bb"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:322b58d6b91b303713d224a661911360"/>
    <ns4:toxicity>In rats, lethality is greater than 100 mg/kg.</ns4:toxicity>
    <ns4:substructure>Cyanides</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:a9d72ff8d93b080cadd433c57f979d37"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L02BG03"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_9"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:RE36617"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:64ec7a065e43780351382ca8ecd6d103"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01217_6"/>
    <ns4:substructure>Cumenes and Derivatives</ns4:substructure>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB00481">
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2101356"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:5393763"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:8772"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4d1948e403f641887747ddfdd191e9dd"/>
    <ns4:substructure>Benzoyl Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_17"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_12"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:136"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB00481"/>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:937c62ae374f5476796c309178516b3e"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_7"/>
    <ns4:synonym>LY-139481</ns4:synonym>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00286_DB00481"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_8"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_18"/>
    <ns4:substructure>Anisoles</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_16"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_4"/>
    <ns4:substructure>Benzothiophenes</ns4:substructure>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_9"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00375_DB00481"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/gtp:2820"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00481_DB00977"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0002-4165-02"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:50f8018e03343e3ef9052188e1b6d7ac"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_6"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00481_1"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00481_DB01357"/>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/raloxifene.html"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/ahfs:68:16.12"/>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00481_DB01432"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00269_DB00481"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_10"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00481_DB04573"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:caa2f904b4b08155f8e4a58d9222f4a4"/>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:ada28c8d82a35f4d44932bb9e5abb16c"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00255_DB00481"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:half-life>27.7</ns4:half-life>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:869"/>
    <ns4:substructure>Ketones</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8130e0f80af50eaf75a28304982a0e74"/>
    <ns4:substructure>Piperidines</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_15"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_14"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pharmgkb:PA451221"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Raloxifene"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_3"/>
    <ns4:protein-binding>95%</ns4:protein-binding>
    <ns4:food-interaction>Avoid alcohol.</ns4:food-interaction>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00481_DB00882"/>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic/raloxif.htm"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_5"/>
    <ns4:substructure>Phenylpropenes</ns4:substructure>
    <ns4:substructure>Aliphatic and Aryl Amines</ns4:substructure>
    <ns4:category>Approved</ns4:category>
    <ns4:volume-of-distribution>* 2348 L/kg [oral administration of single doses ranging from 30 to 150 mg]</ns4:volume-of-distribution>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_11"/>
    <ns4:substructure>Chalcones</ns4:substructure>
    <ns4:biotransformation>Hepatic, raloxifene undergoes extensive first-pass metabolism to the glucuronide conjugates: raloxifene-4'-glucuronide, raloxifene-6-glucuronide, and raloxifene-6, 4'-diglucuronide. No other metabolites have been detected, providing strong evidence that raloxifene is not metabolized by cytochrome P450 pathways</ns4:biotransformation>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8be1de9191eec2dec03cd80888b77ff5"/>
    <rdfs:label xml:lang="en">Raloxifene [drugbank:DB00481]</rdfs:label>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:c0b36bcdbdbd6a3cba0bde8bf6364b8c"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:4d23319cc446077177b9a89dcba1d840"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2158400"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/bindingdb:19441"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:6458811"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:4859"/>
    <ns4:substructure>Phenyl Esters</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00481_DB00930"/>
    <ns4:manufacturer>Eli lilly and co</ns4:manufacturer>
    <ns4:xref rdf:resource="http://bio2rdf.org/dpd:2239028"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:5035"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8a7d4af18b64df6b29be9483344342ef"/>
    <dcterms:description xml:lang="en">A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. [PubChem]</dcterms:description>
    <ns4:substructure>Phenols and Derivatives</ns4:substructure>
    <ns4:mechanism-of-action>Raloxifene binds to estrogen receptors, resulting in differential expression of multiple estrogen-regulated genes in different tissues. Raloxifene produces estrogen-like effects on bone, reducing resorption of bone and increasing bone mineral density in postmenopausal women, thus slowing the rate of bone loss. The maintenance of bone mass by raloxifene and estrogens is, in part, through the regulation of the gene-encoding transforming growth factor-β3 (TGF-β3), which is a bone matrix protein with antiosteoclastic properties. Raloxifene activates TGF-β3 through pathways that are estrogen receptor-mediated but involve DNA sequences distinct from the estrogen response element. The drug also binds to the estrogen receptor and acts as an estrogen agonist in preosteoclastic cells, which results in the inhibtion of their proliferative capacity. This inhibition is thought to contribute to the drug's effect on bone resorption. Other mechanisms include the suppression of activity of the bone-resorbing cytokine interleukin-6 promoter activity. Raloxifene also antagonizes the effects of estrogen on mammary tissue and blocks uterotrophic responses to estrogen. By competing with estrogens for the estrogen receptors in reproductive tissue, raloxifene prevents the transcriptional activation of genes containing the estrogen response element. As well, raloxifene inhibits the estradiol-dependent proliferation of MCF-7 human mammary tumor cells in vitro. The mechansim of action of raloxifene has not been fully determined, but evidence suggests that the drug's tissue-specific estrogen agonist or antagonist activity is related to the structural differences between the raloxifene-estrogen receptor complex (specifically the surface topography of AF-2) and the estrogen-estrogen receptor complex. Also, the existence of at least 2 estrogen receptors (ERα, ERβ) may contribute to the tissue specificity of raloxifene. </ns4:mechanism-of-action>
    <ns4:route-of-elimination>Raloxifene is primarily excreted in feces, and less than 0.2% is excreted unchanged in urine.</ns4:route-of-elimination>
    <ns4:substructure>Cinnamaldehydes</ns4:substructure>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:0d163419cd19cc76b1254df76b140f49"/>
    <ns4:brand>Evista</ns4:brand>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:7bee213832292f1d1685c7e46f011925"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46506514"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00451_DB00481"/>
    <rdfs:seeAlso rdf:resource="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/evi1169.shtml"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6030"/>
    <ns4:indication>For the prevention and treatment of osteoporosis in post-menopausal women, as well as prevention and treatment of corticosteroid-induced bone loss. Also for the reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis or have a high risk for developing breast cancer.</ns4:indication>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4924"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:8cb85c0619090c89d296c9568517a84b"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/iuphar:2820"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:84449-90-1"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pdb:RAL"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:3811"/>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB00481"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00481_DB04574"/>
    <ns4:pharmacology>Raloxifene, a selective estrogen receptor modulator (SERM) of the benzothiophene class, is similar to tamoxifen in that it produces estrogen-like effects on bone and lipid metabolism, while antagonizing the effects of estrogen on breast and uterine tissue. Raloxifene differs chemically and pharmacologically from naturally occuring estrogens, synthetic steroidal and nonsteroidal compounds with estrogenic activity, and antiestrogens. Estrogens play an important role in the reproductive, skeletal, cardiovascular, and central nervous systems in women, and act principally by regulating gene expression. When estrogen binds to a ligand-binding domain of the estrogen receptor, biologic response is initiated as a result of a conformational change of the estrogen receptor, which leads to gene transcription through specific estrogen response elements of target gene promoters. The subsequent activation or repression of the target gene is mediated through 2 distinct transactivation domains of the receptor: AF-1 and AF-2. The estrogen receptor also mediates gene transcription using different response elements and other signalling pathways. The role of estrogen as a regulator of bone mass is well established. In postmenopausal women, the progressive loss of bone mass is related to decreased ovarian function and a reduction in the level of circulation estrogens. Estrogen also has favourable effects on blood cholesterol.</ns4:pharmacology>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C07228"/>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB00481_2"/>
    <ns4:category>Antihypocalcemic Agents</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_20"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_19"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB00481_13"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:G03XC01"/>
    <ns4:substructure>Thiophenes</ns4:substructure>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6020"/>
    <ns4:absorption>Approximately 60% of an oral dose is absorbed, but presystemic glucuronide conjugation is extensive. Absolute bioavailability of raloxifene is 2.0%</ns4:absorption>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00481_DB00783"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB01873">
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2449"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_9"/>
    <rdfs:label xml:lang="en">Epothilone D [drugbank:DB01873]</rdfs:label>
    <ns4:xref rdf:resource="http://bio2rdf.org/pdb:EPD"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_4"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_16"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:161"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:3813699"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Epothilone"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_10"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:C12039"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_1"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2601"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2578"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_3"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB01873"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2444"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_5"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_8"/>
    <ns4:mechanism-of-action>The principal mechanism of the epothilone class is inhibition of microtubule function. Microtubules are essential to cell division, and epothilones therefore stop cells from properly dividing. </ns4:mechanism-of-action>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_15"/>
    <ns4:category>Experimental</ns4:category>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2536"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_11"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB01873"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2342"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2539"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_6"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2480"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2565"/>
    <ns4:indication>Investigated for use/treatment in colorectal cancer, lung cancer, breast cancer, solid tumors, and prostate cancer.</ns4:indication>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_13"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46508361"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_7"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:2499"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_12"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:189453-10-9"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:29"/>
    <ns4:category>Cytochrome P450Epok inhibitor</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_2"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:46936246"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_17"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_18"/>
    <ns4:synonym>KOS-862</ns4:synonym>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01873_14"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB01259">
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_11"/>
    <ns4:brand>Tycerb</ns4:brand>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01259_DB02546"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:1588"/>
    <ns4:substructure>Sulfonyls</ns4:substructure>
    <rdfs:seeAlso rdf:resource="http://www.drugs.com/cdi/lapatinib.html"/>
    <ns4:substructure>Ethers</ns4:substructure>
    <ns4:substructure>Sulfones</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01259_DB01623"/>
    <dcterms:description xml:lang="en">Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug Capecitabine. Lapatinib is human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.</dcterms:description>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01030_DB01259"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:181006"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4118"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00755_DB01259"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_16"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_3"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01259_DB06697"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:L01XE07"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:567"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_6"/>
    <ns4:mechanism-of-action>Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both epidermal growth factor receptor (HER1/EGFR/ERBB1) and human epidermal growth factor receptor type 2 (HER2/ERBB2)with a dissociation half-life of &amp;ge;300 minutes. Lapatinib inhibits ERBB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-florouracil (the active metabolite of capecitabine) were used in combination in the 4 tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro. These in vitro findings suggest non-cross-resistance between these two agents.</ns4:mechanism-of-action>
    <ns4:xref rdf:resource="http://bio2rdf.org/pdb:FMM"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00539_DB01259"/>
    <ns4:substructure>Benzyl Alcohols and Derivatives</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46507141"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00193_DB01259"/>
    <ns4:protein-binding>Highly bound (&amp;gt;99%) to albumin and alpha-1 acid glycoprotein</ns4:protein-binding>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D04024"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00582_DB01259"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01259_DB06708"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_17"/>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2413134"/>
    <ns4:substructure>Furans</ns4:substructure>
    <ns4:substructure>Quinazolines</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/ndc:0173-0752-00"/>
    <ns4:category>Approved</ns4:category>
    <ns4:toxicity>There has been a report of one patient who took 3,000 mg of lapatinib for 10 days. This patient had grade 3 diarrhea and vomiting on day 10.</ns4:toxicity>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:7157466"/>
    <ns4:substructure>Phenols and Derivatives</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_14"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_7"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4924"/>
    <ns4:substructure>Heterocyclic compounds</ns4:substructure>
    <rdfs:seeAlso rdf:resource="http://www.rxlist.com/cgi/generic/tykerb.htm"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/chebi:49603"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00864_DB01259"/>
    <ns4:transporter rdf:resource="http://bio2rdf.org/drugbank_target:5300"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_9"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_18"/>
    <ns4:packager rdf:resource="http://bio2rdf.org/drugbank_resource:d8ba9d7456858777c306fd8433eeca10"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB01259"/>
    <ns4:substructure>Sulfoxides</ns4:substructure>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:2317589"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_4"/>
    <ns4:substructure>Anilines</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/bindingdb:5445"/>
    <ns4:absorption>Absorption following oral administration of lapatinib is incomplete and variable.</ns4:absorption>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_15"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01036_DB01259"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00726_DB01259"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:844"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_13"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00976_DB01259"/>
    <ns4:biotransformation>Lapatinib undergoes extensive metabolism, primarily by CYP3A4 and CYP3A5, with minor contributions from CYP2C19 and CYP2C8 to a variety of oxidated metabolites, none of which accounts for more than 14% of the dose recovered in the feces or 10% of lapatinib concentration in plasma.</ns4:biotransformation>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:388082-78-8"/>
    <ns4:substructure>Cyanamides</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB01259_DB01624"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:6016"/>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Lapatinib"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_10"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:category>Antineoplastic Agents</ns4:category>
    <ns4:product rdf:resource="http://bio2rdf.org/drugbank_resource:f4ccfaaaf49c62e1cb08f33e72b8eabb"/>
    <ns4:half-life>Single-dose terminal half life: 14.2 hours
Effective multiple-dose half life: 24 hours</ns4:half-life>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_5"/>
    <ns4:manufacturer>Smithkline beecham corp dba glaxosmithkline</ns4:manufacturer>
    <ns4:substructure>Anisoles</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_12"/>
    <ns4:synonym>FMM</ns4:synonym>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00246_DB01259"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:substructure>Halobenzenes</ns4:substructure>
    <ns4:route-of-elimination>Lapatinib undergoes extensive metabolism, primarily by CYP3A4 and CYP3A5, with minor contributions from CYP2C19 and CYP2C8 to a variety of oxidated metabolites, none of which accounts for more than 14% of the dose recovered in the feces or 10% of lapatinib concentration in plasma.</ns4:route-of-elimination>
    <ns4:patent rdf:resource="http://bio2rdf.org/uspatent:6391874"/>
    <ns4:substructure>Aliphatic and Aryl Amines</ns4:substructure>
    <rdfs:label xml:lang="en">Lapatinib [drugbank:DB01259]</rdfs:label>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:category>Small molecule</ns4:category>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00656_DB01259"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:4512"/>
    <ns4:pharmacology>Lapatinib is a small molecule and a member of the 4-anilinoquinazoline class of kinase inhibitors. An anti-cancer drug, lapatinib was developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. </ns4:pharmacology>
    <ns4:dosage rdf:resource="http://bio2rdf.org/drugbank_resource:f05d1638fe0e8fb62662631319b00159"/>
    <ns4:substructure>Phenyl Esters</ns4:substructure>
    <ns4:substructure>Aryl Halides</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00706_DB01259"/>
    <ns4:substructure>Aromatic compounds</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_8"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01259_2"/>
    <ns4:substructure>Benzene and Derivatives</ns4:substructure>
    <ns4:experimental-property rdf:resource="http://bio2rdf.org/drugbank_resource:experimental_property_DB01259_1"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:208908"/>
    <ns4:indication>Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.</ns4:indication>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB01259"/>
    <ns4:substructure>Pyrimidines and Derivatives</ns4:substructure>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB01564">
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_8"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:146"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_16"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_6"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_15"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_9"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_3"/>
    <ns4:category>Small molecule</ns4:category>
    <ns4:pharmacology>Calusterone is a 17-alkylated orally active androgenic steroid. Calusterone may alter the metabolism of estradiol and reduce estrogen production. Calusterone has been investigated for possible antitumor properties.</ns4:pharmacology>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_14"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_12"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_10"/>
    <ns4:indication>An anabolic steroid which can theoretically aid in restauration and buildup of certain tissues, especially muscle. It is similar to synthetic testosterone and is still in early investigation. It was also investigated for use as a treatment for metastatic breast cancer.</ns4:indication>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_13"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_4"/>
    <dcterms:description xml:lang="en">A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.</dcterms:description>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_11"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB01564"/>
    <ns4:affected-organism>Humans and other mammals</ns4:affected-organism>
    <ns4:substructure>Steroids and Steroid Derivatives</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/chemspider:26239"/>
    <ns4:category>Illicit</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_7"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_2"/>
    <ns4:substructure>Alcohols and Polyols</ns4:substructure>
    <ns4:substructure>Ketones</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_17"/>
    <ns4:kingdom>Organic</ns4:kingdom>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB01564"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:46507441"/>
    <ns4:substructure>Alkanes and Alkenes</ns4:substructure>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:17021-26-0"/>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_1"/>
    <ns4:category>Androgens</ns4:category>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:28204"/>
    <rdfs:label xml:lang="en">Calusterone [drugbank:DB01564]</rdfs:label>
    <ns4:synonym>17-beta-Hydroxy-7-beta,17-alpha-dimethylandrost-4-ene-3-one</ns4:synonym>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB01564_5"/>
    <ns4:mechanism-of-action>The effects of calusterone in humans most likely occur by way of two main mechanisms: by activation of the androgen receptor, and by conversion to estradiol and activation of certain estrogen receptors.
Using testosterone as the prime example, free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5&amp;alpha;-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5&amp;alpha;-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.</ns4:mechanism-of-action>
    <ns4:substructure>Cyclohexenes and Derivatives</ns4:substructure>
    <ns4:brand>Methosarb</ns4:brand>
  </rdf:Description>
  <rdf:Description rdf:about="http://bio2rdf.org/drugbank:DB06713">
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB06697_DB06713"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/atc:G03AA13"/>
    <ns4:enzyme rdf:resource="http://bio2rdf.org/drugbank_target:2202"/>
    <ns4:substructure>Alkanes and Alkenes</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_14"/>
    <ns4:mechanism-of-action>Norelgestromin inhibits estrone sulfatase, which converts sulfated steroid precursors to estrogen during pregnancy. Norgelgestromin/ethinylestradiol suppresses follicular development, induces changes to the endometrium, which decreases chances of implantation and thickens the cervical mucus, impeding sperm swimming into the uterus. It also has similar agonisting binding affinities as its parent compound, Norgestimate, for progesterone and estrogen receptors.
</ns4:mechanism-of-action>
    <ns4:xref rdf:resource="http://bio2rdf.org/cas:53016-31-2"/>
    <ns4:substructure>Alcohols and Polyols</ns4:substructure>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_10"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:136"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_5"/>
    <ns4:target rdf:resource="http://bio2rdf.org/drugbank_target:614"/>
    <rdf:type rdf:resource="http://bio2rdf.org/drugbank_vocabulary:Drug"/>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00307_DB06713"/>
    <owl:sameAs rdf:resource="http://identifers.org/drugbank/DB06713"/>
    <ns4:mixture rdf:resource="http://bio2rdf.org/drugbank_resource:Ortho-Evra"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemsubstance:99443265"/>
    <ns4:substructure>Hydroxy Compounds</ns4:substructure>
    <ns4:ddi-interactor-in rdf:resource="http://bio2rdf.org/drugbank_resource:DB00930_DB06713"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_13"/>
    <ns4:substructure>Oximes and Derivatives</ns4:substructure>
    <ns4:kingdom>Organic</ns4:kingdom>
    <ns4:substructure>Cyclohexenes and Derivatives</ns4:substructure>
    <rdfs:seeAlso rdf:resource="http://www.drugbank.ca/drugs/DB06713"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_15"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_7"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/pubchemcompound:13752005"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_1"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_8"/>
    <ns4:substructure>Imines</ns4:substructure>
    <ns4:substructure>Steroids and Steroid Derivatives</ns4:substructure>
    <ns4:category>Small molecule</ns4:category>
    <rdfs:seeAlso rdf:resource="http://en.wikipedia.org/wiki/Norelgestromin"/>
    <ns4:category>Contraceptives</ns4:category>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_6"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_2"/>
    <void:inDataset rdf:resource="http://bio2rdf.org/bio2rdf_dataset:bio2rdf-drugbank-20121008"/>
    <ns4:pharmacology>Norelgestromin is used for contraception and menopausal hormonal therapy transdermally or in combination with ethinyl estradiol as a vaginal ring. Norelgestromin, in combination with ethinyl estradiol inhibits ovulation by suppressing gonadotropins. </ns4:pharmacology>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_12"/>
    <dcterms:description xml:lang="en">Norelgestromin is a drug used in contraception. Norelgestromin is the active progestin responsible for the progestational activity that occurs in women after application of ORTHO EVRA patch.</dcterms:description>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_9"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_11"/>
    <rdfs:label xml:lang="en">Norelgestromin [drugbank:DB06713]</rdfs:label>
    <ns4:indication>Norelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy.</ns4:indication>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_3"/>
    <ns4:calculated-property rdf:resource="http://bio2rdf.org/drugbank_resource:calculated_property_DB06713_4"/>
    <ns4:xref rdf:resource="http://bio2rdf.org/kegg:D05205"/>
    <ns4:substructure>Alkynes</ns4:substructure>
    <ns4:category>Approved</ns4:category>
  </rdf:Description>
</rdf:RDF>
